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SUMMARY OF CO NTRI BUTION TO KNOWLEDGE OF THIS INVESTIGATION 
The present i nvestigation was undertaken in order to clarify 
the cl i nica l and metabolic effects of the menopause following 
bilateral oophorectomy in the human female and to evaluate 
the role of subsequent replacement exogenous oestrogen 
therapy . To this end pertinent clinical and laboratory 
studies were carried out. It is considered that the 
followi ng contributions to knowledge have been made : 
l o The symptoms and clinical signs d i rectly related to endogenous 
oestrogen withdrawal following bilateral oophorectomy have 
been clarified and defined . 
2. Symptoms responding to exogenous oestrogen therapy have been 
differenti ated from those responding to placebo (general 
supportive ) therapy. 
3 . The ability of exogenous oestrogens to produce a feeling of 
well-being in postmenopausal females is statisticall y 
substantiated . 
4 . The parabasal cell is shown to be the best cytologic index 
of the oestrogenic status of the postmenopausal female. Claims 
for an i ncrease of vaginal superficial cells with exogenous 
oestrogen t herapy are refuted. 
5. Bi lateral oophorectomy . in the female of reproductive age is 
shown to have no effect for up to 2 years on the total serum 
cholester ol level . Oestrogen therapy, however, reduced the 
level of serum cholesterol in oophorectomized females. 
6 . The effects of b i lateral oophorectomy on plasma calcium and 
inorgani c phosphorus are shown. The ability of oestrogen to 
l ower plasma calcium and phosphorus is demonstrated and the 
possible explanation and implication of these findings is 
discussed . 
7 . A controlled comparative evaluation of two different fo rms 
of oestrogen demonstrates different oestrogens to have 
different effects. Moreover, endogenous and exogenous 
oestrogens are shown to be not entirely similar in their 
clinical and metabolic effects. 
8 . The specific short-term sequelae of oophorectomy are 
demonstrated and the current role of exogenous oestrogen 
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INTRODUCT ION AND REVIEW 
OF THE LITERATURE 
1 . 1 INTRODUCTION 
There i s a paucity of establi shed scientific data 
relating to the human climacteric, whether natural or 
induced by surgical bilateral oophorectomy (castration. 
The 'climacteric' is the counterpart of puberty and 
is the transitory phase between sexual maturity and old age. 
The 'menopause' refers only to cessation of menstruation and 
occurs at a point of time during the climacteric. The years 
preceding the menopause may be called the 'premenopause' 
and the years following it the 'postmenopause' . The 
menopause is merely one manifestation of the climacteric 
and precedes complete cessation of ovarian function by several 
months or years {Jeffcoate, 1967) . The 'senium' is the stage 
of life characterised by the gradual transition into old age 
(senility. Although common usage tends to equate the terms 
'climacteric' and 'menopause' the str ict defini tion of these 
will be adhered to in the present thesis {Kaiser a n d 
Daume, 1965 • 
Notable defi ciencies in the English medical literature 
at the time of i nitiation of this thesis were as follows : 
1. The real c l inical and metabolic changes related specifically 
to oestrogen withdrawal at the climacteric or following 
bilateral oophorectomy . 
2 . The short, medium and long term effects of bilateral 
oophorectomy on the pre- and postmenopausal female. 
3 . The effect of exogenous oestrogen admini stration on such 
pati ents . 
4 . The relati onshi p between exogenous (therapeutic oestr ogens 
and endogenous ov arian oestrogens and the question as to 
whether their effects on the human female are alike or differ. 
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5 . Comparative clinical trials, statistically analysed, between 
different forms of exogenous oestrogen . 
6. The relationship between therapeutic oestrogen effects and 
placebo effects . 
Two further considerations influenced the author to 
undertake the present study. The first was the increasing 
number of women undergoing surgical castration, often as an 
adjunct to other gynaecologica sur gery or as a therapeutic 
measure for carcinoma of t he breast; the second was the 
recent tendency to prescribe oestrogens to all postmenopausal 
women as a panacea against age ' ng . It was therefore considered 
necessary that a broad approach to t he above problems be made. 
Accordingly, a clinical research pro j ect taking such factors 
into account was planned and initiated . Several aspects of 
this investigation have been satisfactorily studied ny other 
authors. The project as a whole, however, 1s considered 
unique in that, to the best of the author's knowledge, no 
other investigation exists 1n which so many clinical and 
biological parameters have been measured at the same time in 
an identical experimental population compr1sing such varying 
control groups and which have then been subjected to 
meticulous statistical analysis. 
This thesis is based on the results of the above clinical 
research and was under taken dur ng the tenure of a full-time 
Lecturer post in the Department of Gynaecology, University of 
Cape Town and the Groote Schuur Hospital, Cape Town. 
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1 . 2 HISTORICAL BACKGROUND 
1.2.1 CLIMACTERIC (MENOPAUSE) 
The prevailing view of the menopause until the turn of the 
nineteenth century was one of despair, as evidenced by the 
following quotation from Colombat's chapter on the 'Change of 
Life' ( 1850) 
'Compelled to yi eld to the power of time,women 
now cease to ex i st as for the species, and henceforward 
live only for themselves . Their features are stamped 
wi th t he impress of age, and their gen i tal or gans are 
s ea l ed wi th t h e si gnet of s ter i lity .... . " It is t he 
d i ctate of pruden c e t o av o i d all such c ir cumstances as 
might t e nd to awaken an y ero tic th oughts i n th e mi nd 
a rid reanimate a sent i ment th at ought rat h e r to become 
e xt i nct · . .. .. i n fi ne, eve ry th i ng calculated t o cause 
r egret for charms tha t a r e l ost, and en j oyments that 
are ended forever' . 
Fortunately a more modern view of the problem of the menopause 
began in the last decade of the nineteenth century, from which 
time reports of physiological, pathological and mental changes 
started to appear in the literature . 
1.2.2 SURGICAL REMOVAL OF OVARIES 
In 1685 Justice Theodorus Schorkopff published the earliest 
feature devoted entirely to ov~rian cysts and suggested 
extirpation as a cure - 'prov i ded' he added ' t he op eration 
were not too cruel and ha zardous' . He did not, however, perform 
the operation and the contributions of Ephrai m McDowell 
(1771 - 1830) form the fundamental knowledge upon which a bdominal 
gynaecological surgery rests. The year 1809 marked an important 
advance in gynaecological therapy and, indeed, a milestone in 
abdominal surgery. In . that year McDowell, after fourteen years 
of practice in the frontier town of Danville, Kentucky, 
successfully performed the first ovariotomy. He fully realized 
that the procedure was an experimental one and the first report 
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only appeared in 1816. For many years the profession in general 
failed to give approval and to Sir Thomas Spencer Wells 
(1818 - 1897) must be 'accorded the credit of having placed 
ovar i otomy in the position not only of an acknowledged operation, 
but one of the most successful of one of the great operations 
of surgery' (Lawson Tait). Charles Clay (1801 - 1893) may be 
called the 'father of ovariotomy' in Britain because he performed 
the first operation in 1842 (Kerr, J.M. Munro et al, 1954). 
As time went on he did so many of these operations that he used 
to reckon his performances by the ton, thinking nothing of 
referring to 2,000 pounds by weight removal of ovarian tumours 
per month. 
Robert Battey (1828 - 1895) was the first to suggest the 
operation of oophorectomy for such conditions as dysmenorrhoea 
and neuroses. Battey performed the first oophorectomy on August 
27, 1872. He attempted to justify the operation of remova l of 
normal ovaries by stating 'the removal of both ovaries puts an 
end to ovulation entirely and this determines the menopause or 
change of life; whereby I have hoped, through the intervention 
of the great nervous . revolution which ordinarily accompanies the 
climacteric, to uproot and remove serious sexual disorders and 
re-establish the general health'. He did qualify this further, 
perhaps somewhat prophetically, by stating that 'I 'believe these . 
organs should alone be sacrificed for grave causes, and then only 
as a dernier resort, when the hitherto recognized resources of 
our art have been expended in vain' . 
Since the above early development the operation of bilateral 
oophorectomy has become a routine practice at hysterectomy 
performed by some gynaecologists. The ostensible reason is to 
prevent the subsequent development of ovarian malignancy. Heated 
controversy exists as to the justification for the procedure, as 
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evidenced by the enormous literature that. has accumulated a~d 
which is reviewed under 1.5. 
1.2.3 OVARIAN (ORGANO) THERAPY 
Organotherapy or glandular therapy was a very ancient form of 
treatment (Ricci, 1945 and 1950). The Egyptians were known to eat 
the penis of an ass as a cure for impotence. The Greeks and Romans 
prescribed the testicles of the ass for this purpose. At the age 
of 72, Brown-Sequard (1889) reported before the Societ~ de Biologie 
of Paris (June 1, 1888) that he had rejuvenated himself by 
injections of ' test i cu l ar juice' The improvement in health 
manifested itself in greater body vigour, better vesical 
(sphincteric ) action and better intestinal acti vity. According to 
Brown-Sequard, Augusta Brown used testicular extract to combat 
feminine debility. 
At the close of the nineteenth century ovarian therapy was 
limited to the administration of crude ovaries, ovarian juice 
(sue ovarien) , powdered ovaries and powdered ovarian tablets. 
These substances were used for conditions such as physiological 
and surgical menopause, dysmenorrhoea and adiposity (Ricci, 1945). 
1.2.4 THE DEVELOPMENT OF OESTROGENIC HORMONES 
It is generally accepted that the first genuine belief in 
the existence of an 'internal secretion' was voiced by Th~ophile 
de Bordeu in 1775. The actual term 'internal secretion' was 
first employed by Claude Bernard in 1855 in a lecture at the 
, 
College de France (Kerr, J.M. Munro et al, 1954). Early this 
century William Baylis and E . H. Starling were dissatisfied with 
the term 'internal secretion' and in search of a better consulted 
various people, including William Hardy who, after discussion 
with W. T. Vesey of Cambridge suggested the word 'Hormone' 
(Kerr, J.M. Munro et al, 1954). 
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In 1849 came the first factual discovery of the physiology o f 
the seK organs and their hormones when A.A. Berthold showed that 
the transplantation of cocks' testes into some other part of 
the body prevented the atrophy of the cock's comb which usually 
followed castration. He attributed this result to the influence 
exerted by the testes on the blood and thence on the body as a 
whole. 
It was not until the present century that the modern conception 
of ovarian physiology took shape. In 1912 Adler produced the 
changes of oestrus by injecting into virgin animals watery 
extracts of ovary. Estimation of oestrogenic effect on vaginal 
smears is based on an observation by Stockard and Papanicolaou 
(1917) that the vaginal epithelium of rodents becomes cornifi ed 
at the onset of oestrus . The reaction occurs not only in mature 
animals but also in immature and ovariectomized animals. It 
was the recognition of this last fact by Allen and Do i sy in 1924 
that gave origin to their test for the assessment of the activity 
of oestrogens (Kerr et al, 1954). Oestrin was the name given 
in 1926 by Parkes and Bellerby to the hormone extracted from 
the ovary by fat solvents. 
Butenandt, a Nobel Prize winner for chemistry, succeeded 
with other research workers in 1929 in isolating and obtaining 
in pure form a hormone from the urine of pregnant women which 
was eventually called oestrone. Somewhat later oestriol was 
discovered in human pregnancy urine. The structural formulae 
of these hormones was worked out by Butenandt (1930) and others. 
It was not until 1940 that the presence of B-oestradiol was 
demonstrated in human pregnancy urine and in the placenta. 
Oestradiol is the most effective oestrogen in the female that 
is known today. 
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1.3 CLINICAL EFFECTS OF THE CLIMACTERIC 
There is virtually no published work relating specific 
symptoms or signs with oestrogen production or excretion. 
Hence the evaluation and precise assessment of clinical features 
thought to be entirely a result of the climacteric is extremely 
difficult. Thus, the majority of clinical features ascribed to 
this non-specific period in the human life cycle are merely 
assumptions and may be no more than coincidental features in 
a generally ageing population (Papanicolaou et al, 1969a). 
The only known factors governing the age of the menopause 
are familial, racial and possibly socio-economic status. The 
menopause usually occurs between the ages of 45 and 50 years 
with an average of 47 years in Great Britain and the United States 
of America (Jeffcoate, 1967). The mean age of the menopause 
appears to be rising (Frommer, 1964). No statistics are available 
for the South African population. 
There is in the literature little information concerning the 
number of women who have sufficient symptoms at the time of the 
menopause to seek medical advice. A statistical study of 1,000 
women in England indicated that 15.8 per cent had no symptoms 
at the time of the menopause, 62.3 per cent had only hot flushes 
for an average duration of two years and 89.7 per cent carried 
on their daily activities without interruption (Sub-Committee 
of Council of Medical Women's Federation of England, 1933). 
Although some reported that as many as 75 per cent of women have 
distressful symptoms at the menopause (Hawkinson, 1938; 
W~lson, R.A . and Wilson, T.A., 1963) it is more generally agreed 
that 10 to 15 per cent of women will present themselves for 
medical advice for symptoms attributed to the climacteric 
(Novak, 1954; Newton and Odom, 1964). 
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Furthermore·, - the nature and incidence of symptomatology varies 
in different educational, racial and population groups (Rogers, 
1956 a; Newton and Odom, 1964 ). Any investigation into the 
climacteric therefore needs meticulous selection of clinical 
material . 
The one definite feature of the climacteric is the menopause . 
Premenopausal symptoms never occur, according to Jeffcoate 
(1 967 ) for the reason that the ovary continues to function, 
alt~ough to a lesser extent, until some time after the menopause. 
Other workers do not agree with this viewpoint; although the 
only premenopausal symptom they describe in fact r elates to an 
alterati on in the menstrual cycle (irregularity, i ncrease in 
length of cycle or decrease in flow (Newton and Odom, 1964; 
Rogers, 1956 a; Wilson and Wilson, 1963). 
The symptoms which arise at the menopause are o ften o f 
a psycho.logical nature (Forman, 1968 ) ; in addition , the re is 
frequently evidence of vasomotor i nstability . Many of the 
clinical features are believed to result from a decline and 
eventual failure of ovarian function. This is .discussed 
further under 1.4.1. For convenience the symptomatology and 
untowar d effects of the climacteric are usually classified, 
albeit artificially, into 3 groups as follows : 
AUTONOMIC NERVOUS PSYCHOGENIC FEATURES RELATED TO SYSTEM IMBALANCE METABOLIC CHANGES 
Hot flushes Headaches Senile vaginitis 
Perspiration I nsomnia Atheromatosis and 
Palpitations Mood changes Thrombosis 
Angina pectoris Irritability Skin atrophy 
·Depress i on Breast atrophy 
Frigidity Osteoporosis 
Apprehension Degenerative arthropathy 
Hirsuties 
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It is most likely that the only actual symptoms resulting 
from diminished ovarian activity are amenorrhoea and vasomotor 
instability as manJ.fested by hot flushes (Rogers, 1956 a) • 
The mechanism of the hot flush was studied by Reynolds et al 
{1941 a, 1941 b). The flush is usually described as a sudden 
feeling of heat in the face, neck and chest, associated with 
diffuse or patchy flushing of the skin or perspiration . 
Vasodilatation is followed by vasoconstriction, so after a 
flush comes a cold shiver. The flush is a manifestation of 
vasomotor instability and is brought on particularly by 
excitement or nervousness. The hot flush is the one symp tom 
allowing of definite measurement in that the patient is usually 
able to describe the number of hot flushes suffered per twenty-
four hour period. 
The host of other symptoms such as palpi tations, angina 
pectoris, headaches, irritability, depression, frigidity and 
apprehension that are listed as components of the 'menopau sal 
syndrome' Rogers, 1956 a ) are probably manifestations of the 
psychological disturbances that may occur at this time of life 
and there is no evidence that these symptoms are causally 
related to oestrogen lack (Forman, 1968; Greenblatt, 1963; 
McCandless, 1964; Newton and Odom, 1964; Rogers, 1956 a; 
Squires and Cannell, 1952; Young, 1939 ) . 
Symptoms and signs may be related to metabolic changes. 
Thus atrophic (senile ) vaginitis, resulting directly from 
oestrogen deficiency may· produce symptoms of dyspareunia or 
pruritus vulvae (Jeffcoate, 1967; Rogers, 1956 a ). Furthermore, 
oestrogen deprivation appears to be associated with breast 
atrophy and possibly skin atrophy (Greenblatt, 1963; Jeffcoate, 
1967; Kretzshma.r, 1964; Wilson, R.A . and Wilson, T.A., 1963). 
The clinical and metabolic aspects of the locomotor and cardio-
vascular systems will be discussed below 1 . 4). 
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One of the objectives of thi s thes i s i s to det ermi ne 
whether a relat i onship can be demonstrated between any of the 
above symptoms and oestrogen depri vation, as produced by 
castration . 
11 -
1 • 4 METABOLIC -E·F.FECTS· · OF THE' €LIMACT"E"RIC 
In view of the fact that the menopause occurs at a time 
of life when there is a rising incidence of degenerative disease, 
it is not surpris i ng that a causal relationship between some of 
these disorders and climacter i c metaboli c effects should have 
been postulated . Once again, proof of a direct relationship 
is lacking between oestrogen deprivation and development of any 
particular metabolic derangement or degenerative process . In 
some instances indirect evidence has been produced . 
The metabo l ic effects of the climacteri c wi ll be described 
and discussed in relat i on t o the development o f specific 
degenerative or pathol og i cal processes . 
1.4.1 HORMONE CHANGES 
The climacteric as a phase characterized by i mpor t ant endo-
crinal changes associated with progressive loss of ovarian 
function is reviewed by Riley (1964) . A number of theories have 
been adduced relating endocr i ne function to the sympt omato l ogy 
of the menopause . One of the most wi dely accepted theories 
(Albright, 1936) postulated that the symptoms are caused directly 
by the overproduction of human pituitary gonadotrophins (HPG ) 
while anot her, t hat of 'oestrogen lack' (Heller et al, 1944b) 
proposes that the c l inical features ari se from a decrease in 
the l evels of c i r c u l a ting oestrogens . There i s a lack of 
information regarding hormone excretion patterns in subjects at or 
about the menopause and i n the absence of such data an 
authoritative opinion cannot be given about the validity of the 
hypotheses mentioned above (Papanicolaou et al, 1969a) . 
It is generally accepted that the excretion of oestrogens 
in urine decreases wi th i ncreasing postmenopausal age and 
decreasing ovarian. activity . According to Brown and Matthew (1962) 
the values for total urinary oestrogen seldom exceed 10 pg/ 24 
hours in postmenopausal women, a f i nding which is characteris-
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tically assocj.ated with lack of endometrial stimulation due to 
absence of ovarian function . It is noteworthy that values as 
low as these may be encountered temporarily during the early 
proliferative phase of the menstrual cycle. Carcatzoulis (1 963) 
reported that postmenopausal women always excrete oestrogen at 
a constant rate and the quantity is about one third of that 
excreted in normal menstruating women. Gr~nroos (1965) found 
no correlation between the total urinary oestrogen excretion 
and postmenopausal age . Furuhjelm (1966 ) concluded that the 
excretion of oestrogens in urine decreases with increasing 
postmenopausal age " It is generally agreed that the main 
source of oestrogen in postmenopausal subjects is the adrenal 
cortex {Loraine and Bell, 1966, 1968 ). Procope (19 68 ) , however, 
demonstrated two groups of postmenopausal women differentiated 
by ovarian histology, of which ovarian oestrogens were demonstrated 
in one group . 
Loss of ovarian function is followed by a marked increase in 
the excretion of pituitary gonadotrophins. Papanicolaou et al 
(1969a, 1969b) have suggested that in late reproductive life 
the reciprocal relationship believed to exist between pituitary 
gonadotrophic function and ovarian oestrogen secretion is no 
longer operative and reported that an elevation in luteinizing 
hormone (LH) output to postmenopausal l evels may precede the 
clinical menopause. The increase in HPG is predominantly due 
to an increased secretion of follicle stimulating hormone (FSH) 
although the levels of both FSH and LH are raised (Albert et al, 
1961 ) • 
It is not yet clear whether in perimenopausal women the 
ovaries are under maximum stimulation by the pituitary or 
whether they are still capable of responding to stimulation 
with gonadotrophic hormones (Papanicolaou et al, 1969a), 
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although Poliak et al (1969) are of the opinion that the latter 
is possible. 
Many clinical and experimental observations have suggested 
the existence of functional relationships between the adrenal 
cortex and the ovary (Jones, 1955; Turner, 1955). The excretion 
of total 17-hydroxy-corticosteroids, like that of total 
17-ketosteroids, shows a steady decrease throughout the climacteric 
and postmenopausal years (Borth et al, 1957). Furthermore, 
there are indications that accelerated ageing of collagen may 
I 
be attributed to increased ACTH formation (Verzar, 1968). It 
may thus be theorized that the pathway of decreasing ovarian 
function, decreasing adrenocortical function and resultant 
increased pituitary activity may be one of the factors in the 
aetiology of ageing human tissues. 
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1 . 4 . 2 CHOLESTEROL, CORONARY HEART DISEASE AND OESTROGENS 
The endocrinological control of cholesterol metabolism is 
a complex subject. The interest of the present discussion is 
limited to the effect of endogenous and exogenous oestrogens 
on the serum cholesterol level and to demonstrating the 
reliability of these levels for the prediction of risk of 
developing atheromatosis and coronary artery thrombosis. 
Some investigators have noted that the premenopausal female, 
compared with the human male, is protected against coronary 
accidents (Barr, 1953; Marmorston et al, 1962; Stamler et al, 
1963; Schlesinger and Zoll, 1941). This sex difference is 
alleged to be due to oestrogens. The evidence will be examined. 
The circulating cholesterol is largely synthesized in the 
liver and discharged into plasma bound to lipoproteins. The 
plasma cholesterol pool reflects the net result of a series of 
reactions which are donating sterol to the pool whilst others 
/ are removing sterol (Boyd, 1963). 
Among Western populations and the prosperous moiety of 
non-White populations serum cholesterol and other blood lipids 
rise with age (Keys, 1963; National Centre for Health Statistics, 
1966). Serum cholesterol is thought to increase from about 
180 mg/100 ml in the 20s to about 220 in the 50s (Wyndham, 1969). 
The levels vary, however, in different population groups (Gram and 
Leverton, 1949; Walker, A.R.P., 1968; Wessel et al, 1963). For 
example, Barr (1953) recorded mean levels of 197 in normal women 
aged 18-35 and 252 in normal women aged 45-65. Oliver and 
Boyd (1959) reported mean levels of 217 for women aged 40-49, 
240 for the groups 50-54 and 259 for the 55-59 year olds. 
The risks of coronary thrombosis are said to be seriously 
increased if serum cholesterol levels exceed 250 (Kannel et al, 
1961; Wyndham, 1969). 
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Cholesterol is a precursor of oestrogenic hormones Gual et al, 
1962·; Ryan and Smith, 1961) • Endogenous oestrogens appear to 
influence cholesterol metabolism in at least two ways. There 
is an effect on the biosynthetic mechanism and also an influence 
on the rat e of degradation or excretion (Boyd, 1963 . Thus 
these oestrogens appear to exert an effect on human plasma 
cholesterol and lipid - lipoprotein levels (Barr, 1953; Katz and 
Stamler, 1953; Katz et al, 1958; Marmorston et al, 1962 ). In 
the human female oophorectomy produces an i ncrease in the plasma 
cholesterol concentration of about 15% to 30% of the preoperative 
value (Ol i ver and Boyd, 1959), and spontaneous premature menopause 
may also result in elevation of these levels later in life 
(Sznajderman and Oliver, 1963)~ 
Atheromatosis is a metabolic disease that is i nf l uenced 
by ma ny factors (Bleyland and Wegener, 1969; Chapman and Massey, 
1 96 4; Dr i ll and Riegel, 1958; Doyle et al, 1964; Katz et al, 
195 8; Kurland and Freedberg, 1960). The development of 
atheromatous lesions does not lend itself to precise measurement 
i n the l i ving. However, the extent and severity of coronary 
a t heromatosis determines the risk of ischaemic heart disease 
in a given population (McGill et al, 1963). This presentation 
is concerned with only one phase of atheromatosis, namely, its 
relation to ovarian function and plasma cholesterol. 
Coronary risk factors are those abnormalities demonstrable 
i n persons free of coronary heart disease (CHD) and known to be 
associated with significantly increased risk of developing the 
disease in subsequent years. Numerous prospective studies on 
Western populations have indicated a close correlation between 
the moiety with elevated cholesterol levels and their proneness 
t o ischaemic heart disease (Epstein, 1965; Katz et al, 1958; 
Kanne l e t a l, 1961, 19 64; Morris et al, 19 66 ; Stamler, 1964; 
Stamler et al , 1966 ) . Population groups with hypercholesterolaemia 
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experience four times as many heart attacks as those with l ow 
serum cholesterol levels (Stamler, 1964 ) . This strong relationship 
is well shown in the Framingham study {Kannel et al, 1961, 1964; 
Thomas et al, 1966) and in the Los Angeles heart study (Chapman 
and Massey, 1964). Katz and Stamler (1953) have demonstrated 
experimentally a similar relationship. They noted that feeding 
cholesterol to cockerels produced coronary atherosclerosis. 
In Western populations a similarity exists in the proportions 
of the leading causes of death (Mortality Statistics, 1967 • 
Thus CHD accounts for about a third, cancer a quarter or less 
and 'strokes' 10% to 1.5% of total mortality. An important 
question, therefore, in improving mortality statistics is whether 
long-term reduction of hypercholesterolaemia will in tur n 
reduce the incidence of atheromatosis and subsequent ischaemi c 
heart disease. In this direction it is important to determi ne 
factors respons ible for increasing and for decreasing p l asma 
cholesterol levels (Walker, A.R.P , 1968). 
Considerable evidence, experimental and clinical, i s avai lable 
indicating that endogenous ovarian oestrogen secretion plays a 
key role in protecting women against clinical atheromatous 
(atherosclerotic ) coronary heart disease . This evidence is 
well reviewed by Berkson et al (1964) and key references only 
will be discussed below. 
Numerous studies have been done on the effects of castration 
or premature menopause on the occurrence of both clinical heart 
disease and autopsy evi dence of atherosclerosis in women 
(Higano and Cohen, 1963; Novak and Williams, 1960; Oliver and 
Boyd, 1959; Robinson et al, 1959; Wuest et al, 1953 . Wuest et 
al (1953) compared the degree of sclerosis in hearts of 
bilaterally oophorectomized women with hearts of men and women 
of comparable ages , They found that the degree of coronary 
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sclerosis in the oophorectomized woman was .qr·ea~ tb:au in control 
women but less than in control men. Oliver and Boyd (1959) 
reported that bilateral oophorectomy was followed by the premature 
development of clinical coronary artery disease; similar findings 
were found by Robinson et al (1959). Higano and Cohen (1963) 
reported the risk to be fourfold . Novak and Williams (1960) 
stated that the data of Robinson et al (1954 and Oliver and Boyd 
(1959), being clinical in nature, could not be as objective and 
precise as data obtained at autopsy. Regardless of initial age at 
operation or years intervening before death, they could find no 
significant differences in the incidence of atheroslerosis in 
statistically comparable groups of castrated and control patients 
at autopsy. A follow up study (Williams and Novak, 1963) suggested 
that operation before the age of 40 might be of significance . 
Parrish et al (1967) suspected that an importapt factor overlooked 
by previous writers was the time interval between castrati on and 
the 'expected date' of the normal menopause. From a study of 
autopsy records they found that castrated patients did have an 
excess of coronary atherosclerosis and myocardial infarcts, but 
this was directly related to the time interval from castration to 
'expected menopause' and the time interval from castration to 
death. No excessive coronary atherosclerosis was found in women 
castrated after the age of 41 in contrast to those castrated when 
younger; excessive coronary atherosclerosis became apparent about 
14 years after castration . They concluded that women castrated 
before the age of 40 who were expected to survive more than 14 
years were at high risk of developing coronary heart disease. 
Finally, in a 6 - 20 year follow up study of 35 women who had 
undergone spontaneous premature menopause, Sznajderman and Oliver 
(1963) further supported the view that cessation of ovarian 
activity, whether premature or at the time of a normal menopause 
- l 
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leads to an increase in the incidence of ischaemic-heart disease 
and in serum-lipid levels in later life. 
Thus the evidence as to the protective effect of the 
functioning ovary is convincing . Unfortunately, as yet the 
supporting evidence for the next logical step in this argument 
is not as sound, namely the effect of replacement exogenous 
oestrogen on the female cardiovascular system. 
A wide range of oestrogenic substances have been studied 
for their effects on cholesterol metabolism (Drill and Riegel, 
1958; Nestel et al, 1965). Oestradiol, oestradiol benzoate and 
diethylstilboestrol are more potent than oestrone as regards 
both lipid effects and oestrogenic activity. Ethinyl-oestradiol 
has less effect on lipids and is more potent as an oestrogen than 
oestrone (Drill and Riegel, 1958; Rubin et al, 1951). The table 
below is a summary from Boyd (1963) of a few of the oestrogens 
























(after Boyd, 1963) 
Thus, in the human, the administration of oestrogenic 
substances at certain dosages produces a depression in the plasma 
cholesterol concentration and the dosage necessary to produce 
this effect on· the plasma cholesterol level is in excess of the 
threshold oestrogenic dose (Boyd, 1963). However, there is 
)' 
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insufficient data at this stage to allow more than speculation 
on the possible mode of action of the oestrogens in cholesterol 
metabolism. 
Experimentally, Pick et al (1952 ) have shown that 
administration of oestrogens inhibits coronary atherogenesis 
in cockerels fed a cholesterol supplemented diet. There are no 
comparable studies in man . Oliver and Boyd (1961) administered 
oestrogen to myocardial infarction survivors. They found that, 
although significant reduction of the serum-cholesterol was 
evident throughout the five years of treatment, the continued 
reduction of serum lipids did not improve prognosis once myocardial 
infarction had occurred . Similar findings were reported by 
Marmorston et al (1962 ). Other studies have shown the effects 
of oestrogens on serum lipid patterns in postmenopausal women 
(Robinson et al, 1960; Barr et al, 1953). In most cases 1.25 mg 
of mixed conjugated equine oestrogens daily was adequate to 
produce a fall in serum cholesterol. 
Numerous workers have attempted to prove that exogenous 
oestrogen therapy decreases the incidence of coronary heart 
disease, but there is no conclusive proof to date (Oliver and 
Boyd, 1961; Marmorston et al, 1962; Spritz, 1968; Stamler et al, 
1963). 
Despite the above lack of definite evidence there is a 
growing tendency towards the empirical use of long term exogenous 
oestrogen therapy in the postmenopausal woman to prevent ischaemic 
heart disease (Davis et al, 1961; Davis, 1964; McBride, 1967; 
McEwen, 1965; Wilson and Wilson, 1963; Wilson et al, 1963). 
The discussion presented illustrates that there are still 
many aspects of this complex inter-relationship requiring further 
1 elucidation or conf i rmation . The present study was planned to 
evaluate just two of these aspects, namely the effect of 




oestrogen administration to identical and statistically 
comparabl e g r oups of patient s can cause a lowering of these 
values . 
1.4.3. CALCIUM AND PHOSPHORUS METABOLISM AND OSTEOPOROSIS 
The decreas i ng ovarian function of the climacteric is said 
to be a factor leading to the deve l opment of osteoporosis. 
Postmenopausal osteoporosis has been the subject of several 
reviews (Bassan et al, 1963; Frost, 1961, 1966; He.nneman, 1964) 
• 
and the present discussion is limited to defining the problem 
in terms of the relationship between oestrogen deficiency or 
oestrogen therapy, calcium and phosphorus metabolism and 
osteoporosis . 
It was not until 1 941 t hat Albright et al (1941) described 
osteoporos i s as a clinical entity . l Osteoporosis is a common 
clinical disorder whi ch may cause backache or fracture in the 
elderly. It i s charact e rised by a reduced amount of bony tissue 
per unit volume of bone i n the affect ed part or parts of the 
skeleton. Unlike ost eomalac ia, there are no known specific 
/ 
biochemical abnor malities in osteoporosis and most authors agree 
that ost eoporotic bone , while reduced i n quantity, is essentially 
norma l i n chemical composition . Nordin et al, 1966). 
The investigat i on o f osteoporos i s has been handicapped by 
the lack of satisfactory ob jective radiodiagnostic criteria. 
The Medical Research Counc1l's Mineral Metabolism Unit has 
developed two quantitative measures Brit . Med. J. 1969). 
The f irst method is X-ray dens itometry and the second isotope 
dens itometry . Lanzl and Strandjord (1 965 ) have also reported 
on a radio-isotopic device for measuring bone mineral. 
Unfortunate l y none o f these techniques could be made available 
i n Cape Town at the initiation of the p r esent study. 




osteoporotic process commences or accelerates in women soon 
after the natural or induced menopause .(Albright et al, 1941; 
Meema et al, 1965; Meema, 1963; Nordin et al, 1966; Saville, 
1967). For this reason ~ lbr i ght et al (1941, 1948) attributed the 
condition to gonadal i nsuff i ciency resulting in a reduced rate 
of synthesis of bone collagen matrix). This theory has not 
been substantiated by most isotope kinetic studies (Heaney 
and Whedon, 1958; Nordin, 1959 ) and tends to be refuted by 
histological evi dence suggesti ng bone resorption and normal 
bone formation (Frost, 1961, 1 966) . This recent work (reviewed 
by Nordin et a l , 1964 demonstrating increased bone resorption 
possibly related to calcium deficiency (Harrison et al, 196l) 
rather than decreased bone format i on as the likely ca~se of 
osteoporosis has not only cast doubt on the collagen theory 
but on the role of the gonadal hormones as well (Lafferty et 
al,1964). Although doubt has been accentuated by the absence 
of convincing evi dence that osteoporosis responds to treatment 
with gonadal hormones, it does appear that osteoporosis is 
related to endogenous oestrogen deficiency (Nordin et al, 1966), 
the evidence bei ng circumstantial and not all workers in 
agreement (Ruik ku e t al, 1968; Four man and Royer, 1968). It 
seems that, although the os t eoporosis of postmenopausal women 
may ultimatel y be due to hormonal deficiency, its immediate 
cause mus t lie i n t he regul ati on of calcium absorption or excretion 
(Bronner et al, 1963; Nordi n e t al, 1966; Jasani et al, 1965; 
Young and Nordi n , 1967). 
Factors as described above have focused attention on the 
menopause and therefore on t he effects of the oestrogenic 
hormones on calci um metabol i sm . Jasani et al (1965) considered 
that careful measurement of p l asma calcium might be one way of 
distinguishing whether the negative calcium balance of 
osteo~orosis i s secondary to a primary rise in bone resorption, 
FIGURE I 
THEORETICAL EFFECT of OESTROGEN on P.LASMA CALCIUM 
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or the rise in bone resorption is the result of an external 
negative calcium balance. They theorised that 'if the loss of 
oestr og e n ic activity has a d irect effect upon bone resorption 
a nd i ncreases the release of calcium i nto the plasm~, it will 
tend to rais e the serum calcium and s o also the urinary calcium. 
If, on the other hand , oestro gens tend to i ncrease either the 
re nal tubular reabsorption of calcium or the absorption of 
calcium from the small intestine (or both) then deficiency of 
oestro gen ic hormones (unless ass oc ia ted with an increased calcium 
intake) wou l d tend to lower the plasma calcium and consequently 
increase t he rate of bon e r e sorpt i on i n order to maintain the 
p las ma l eve l . Thus the d ifference between these two processes 
is i n their effect on plasma ca l ci um (see diagramatic 
re pre sentation, Figure I) . Acc ording to one hypothesis, 
oestro gens would tend to l ower urinary calcium and so to raise the 
p las ma lev el and reduce bone res orpt i on; according to the other, 
oestro gens would te nd to lower plasma calcium and so to lower 
ur i nary calcium and i mpro v e calci um balance'. Their preliminary 
results suggested that oestrogens do not raise the plasma calcium 
and that the menopause (oestrogen deficiency) is associated with 
a slight r i se in plasma and urinary calcium. They therefore 
suggested that oestrogenic hormones have an action on the 
blood/ bone equilibrium antagonistic to that of parathyroid 
hormone and that a reduction of oestrogenic activity leads to 
a marginal elevation of plasma calcium and so to hypercalciuria 
and to negative calcium balance. They have suggested, moreover, 
that parathyroid hormone can break down bone more easily when 
oestrogens are not present. The degree of osteoporosis which 
this produces must depend upon the length of time which elapses 
before the subject re-adapts to the new situation. A further 
report Young and Nordin, 1967 ) , showed a significant rise in 
plasma and urinary calcium and phosphorus values after the 
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menopause . In the premenopausal women, fasting plasma calcium 
was 9.32 and the phosphorus 3.31 mg/100 ml. After the natural 
menopause the corresponding values were 9.62 and 3 . 52. After the 
artificial menopause the corresponding values were 9 . 81 and 3.62. 
The rise of plasma and urinary calcium was most apparent during 
the first years after the cessation of menstrual periods. They 
interpreted these changes to mean that the menopause is followed 
by a - rise in bone resorption which leads to a rise i n plasma and 
urinary calcium and phosphorus and Szymendera and Madajewicz (1967) 
have reported similar findings. 
Although the above biochemical changes c a n be reversed by 
• 
oestrogenic hormones (Young et al, 1968) the evidence as to 
improvement of osteoporosis following such therapy is poor . 
Lafferty et al (1964) found that oestrogens primarily reduce bone 
I 
resorption and do not stimulate bone formation. In fact, after 
prolonged administration a secondary decline in bone formati on 
occurred. p ;hus, despite publications suggesting prophylactic 
oestrogen therapy and reports on relief of symptoms, there is 
little evidence of increased bone formation by densitometry, X-ray 
or histological studies / Bassan et al, 1963; Davis et al, 1966; 
Fourman and Royer, 1968; Hernberg, 1960; Lafferty et al, 1964; 
Meema and Meema, 1968; Wallach and Henneman, 1959). 
The present study was planned to incorporate an investigation 
into plasma calcium, phosphorus and alkaline phosphatase levels. 
Thus there was no attempt to demonstrate the development of 
frank osteoporosis; rather an attempt was made to prove one 
step in the pathogenesis of the d i sease . 
Plasma alkaline phosphatas~ levels were performed for 
completeness' sake. There are two important causes for 
raised serum alkaline phosphatase activity; those diseases of 
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bone i n which there is increased osteoblastic activity and 
diseases o f the liver, especially where there is obstruction 
to the outlow o f bile {Brit. Med. J . , 1968 ). These levels, 
therefore , have an established place in the investi gation of 
suspected d iseases of bone. 
1.4 . 4 . VAGINAL SMEAR 
Si nce the early work of Stockard and Papanicolaou (1917) 
numerous workers have confirmed the r e lationship between 
·oestrogen metabolism and the cells of the vaginal epithel i um. 
The literature on postmenopausal vaginal smear has been 
extens i vely and thoroughly reviewed by Gr~nr o s (1 965 • The 
use and method o logy of exfoliative cytology for the evaluation 
; of endocrinological conditions has been r evi ewed by Liu (1968), 
Rakoff (196 1) and Wied (1968 ) . 
The p r oportion of atrophic smears has been found to increase 
with the postmenopausal years Masukawa, 1960) although an 
oestrogen-like effect may be observed in many postmenopausal 
women (St one et al, 1961 } and there is difficulty in overcoming 
differences attributable to age disparity (Stern et al, 1966). 
The v ag inal smear is a bioassay . Relatively few correlative 
s t udi es have been published on the urinary oestrogen output 
and t h e oestrogen effect in vag i nal smear. Gr~nroos 1965) 
found a positive correlation between karyopyrotic i ndex (KI) 
and urinar y output of oestrone, oestradiol and oestriol in 
healthy pos tmenopausal patients . 
thi s corr e l a tion , 
J 
Procope 1968 conf i rmed 
The hormonal evaluations are usually expressed by means o f 
i ndices depending upon the variations between the accepted three 
major cel l type s (superficial, intermediate and parabasal cells}. 
The matur a tion index (Frost, 1958), for example, reflects the 
percentage of superficial, intermediate and parabasal cells 
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present and has the advantage of easy transfer to the computer 
for analysis (Stone et al, 1967). 
Despite the validity of the vaginal smear as a . bioassay of 
the oestrogenic status of the postmenopausal female there is 
doubt as to the use of the vaginal smear as an assessment of 
the need for _or response to exogenous oestrogen therapy 
(Kaufman, 1967). 
A further object of the present study was to determine the 
effect of the surgical menopause (castration) and subsequent 
exogenous oestrogen therapy to the same group of patients on 
the vaginal smear. It was hoped to correlate the vaginal smear . 
with urinary oestrogen levels. Unfortunately it was not 
financially possible to establish a technique to measure total 
or fractionated urinary oestrogens in the Department of 
Gynaecology. 
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1.5 OOPHORECTOMY - INDICATIONS AND INCIDENCE 
The surgical removal of normal ovaries at the time of 
routine abdominal hysterectomy oerformed for beni.gn conditions 
is a controvers i al subject in modern gynaecology. 
The reasons advanced for removal of ovaries are as follows 
1. Prevention of subsequent development of cancer in the 
retained ovaries. 
2. The theory that r etained ovaries have diminished or 
absent function. 
3. High incidence of repeat laparotomy for ovarian 
pathology (Grogan and Duncan, 1955). 
The ovaries are frequently retained in order to: 
1. Prevent development of postoperative menopausal symptoms 
(discussed under section 1 . 3). 
2. Prevent regressive effects related to oestrogen withdrawal 
(discussed under sections 1.3 and 1.4). 
3. Prevent development of osteoporosis (discussed under 1.4 .3 ) . 
4. Prevent development of ischaemic heart disease 
(discussed under section 1.4.2 . ) . 
5. Psychological reasons. 
The poss ible cl i nical and metabolic effects of oophorectomy 
are well reviewed by Murless (1964) and are discussed under 
sections 1.3 and 1 . 4. The indications advanced for removal of 
normal ovaries are discussed below . 
The risk of subsequent development of carcinoma in retained 
ovaries following hysterectomy is generally considered to be 
small. Schabert (1960), reviewing reasons for retaining ovari es, 
reported the incidence to be approximately 2 i n 5,000 
\ 
hysterectomies. This figure is similar to that of 1 - 3,000 to 
5,000 hysterectomies quoted by Jeffcoate (196 7 ). However, 
Bloom (1962) found that 15 (10 . 6%) of 141 cases of primary 
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adenocarcinoma of the ovary from the Johannesburg General 
Hospital had previously had a hysterectomy or other pelvic 
operation performed. In 5 of these cases (3.5%) the ovaries 
had been conserved when the patient was over 50. Counseller 
(1955) reported on 1,500 cases of proved carcinoma of the ovary 
of whom 67 (4.5%) had undergone hysterectomy for a benign 
condition. While 33% of these 67 patients were in the group less 
than 40 years of age, only 4.5% of the ovarian carcinoma occurred 
in that age group. They suggested that oophorectomy should 
therefore be performed only on patients over the age of 40. 
Nevertheless, until the results of further large surveys are 
analysed it is not possible to define the absolute risk of 
subsequent development of carcinoma. 
It has been said that following hysterectomy the ovaries 
soon become functionless. There is, however, evidence to show 
that the ovaries may continue to function for several years after 
hysterectomy (Bancroft-Livingston, 1954; Heller et al, 1941; 
Richards, 1951; Whitelaw, 1958). There is furthermore no 
indication that hysterectomy hastens the onset of the menopause 
(Whitelaw, 1958) and Randall et al (1957) have even suggested 
that the ovaries may produce oestrogen after the menopause. 
Additional evidence to show that conserved ovaries function 
completely normally up to the expected time of the menopause 
was reported subsequent to the completion of this thesis 
(Beavis et al, 1969). 
The incidence of surgical removal of ovaries at hysterectomy 
varies according to current fashion in different gynaecological 
units . Randall and Paloucek (1968) reported that no generally 
accepted criteria for ovarian preservation or indication for 
ovarian removal had been observed in one geographic area during 
the 25 year period reviewed. It is of interest that in the 
annual Clinical Reports of the Division of Gynaecology, 
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University of Cape Town, no statistics relating to removal or 
preservation of ovaries are i ncluded . Hence an analysis in 
this respect in Cape Town is not possible . 
There is therefore good evi dence, as described in the 
aforegoing discussion, that there are advantages to the 
conservation of normal functioning ovaries at the time of removal 
of the uterus. An unanswered questi on,nevertheless, is whether 
exogenous oestrogen therapy following b i lateral oophorectomy 
has the same or similar metabol i c eff ects as retained 
functioning ovaries. The present thes i s attempts to evaluate 
part of this question. 
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1.6 OESTROGEN REPLACEMENT THERAPY 
The general management of the climacteric has been the sub ' ect 
of many reviews (Greenblatt, 1963; J effcoate, 1 960, 1967; 
Rogers, 1956b) . There is also a large literature concerning the 
various preparations of oestrogens and the several routes of 
administration (Brown et al, 1951; Cohen, ~968; Haskins et al, 
1962; Jeffcoate, 1960; Kupperman et al, 1953; Kupperman and Blatt, 
1959; Swyer, 1959 ). Many reports testify to the use of vari ous 
oestrogens for the rel~ef of 'postmenopausal symptoms' (c f Section 
1.3) (Dapunt, 1967; Greenblatt et al, 1962; Greenbla t, 1965; 
Hankin, 1967; Sands, 1967; Wilson e t al, 1966) . Some authors 
suggest a general tonic effect wit~ exogenous oestrogen therapy 
(Davis, 1967; Greenhill, 1 967; Wilson and Wilson, 1963 and a 
preliminary report states that such therapy may prevent 
psychological deterioration in the older woman (Kantor et al, 
1968). Despite this there is a remarkable lack of comparative 
clinical trials in gynaecology, and the choice of an oestrogen 
has still to be based on relatively uncontrolled collective 
experience (Drug and Therapeutics Bulletin, 1968). For thi s 
reason part of the present study entai led a controlled comparative 
evaluation between two forms of oestrogen and a placebo. 
There has been a recent tendency to regard the climacteric 
as a hormone (oestrogen ) deficiency syndroms . Wilson and Wilson 
(1963) have led this school of thought and make a plea for 
'the maintenan ce 0f adequate oe s trogen f rom pubert y t o the grave' . 
In 1963 Wilson et al reported on 'spe ci fi c p roc edures fo r the 
elimination of the men o pause' , Support has come from other 
writers (Bedford, 1967; Davis, 1 964, 1965, 1967 ; Greenblatt, 1963; 
Kushima et al, 1961; McEwen, 1965; McBride, 1967 • The arguments 
presented by these authors for such therapy are incomplete and 
in many instances have no basis i n fact. The essential fallacy is 
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that there is little evidence to show t hat exogenous oestrogen 
therapy has the same effect as t hat of the endogenous ovarian 
oestrogens (discussed in section 1.4 ). There i s thus a strong 
school of thought in disagreement with such empi rical therapy 
(Greenhill, 1967; Novak, 1967; Taylor, 1968). 
Furthermore, long-term exogenous oes t rogen ther apy may not 
be without risk. There is an increas i ng literature r elating 
oestrogen therapy with vascular thrombos i s and embol i sm when 
used for suppression of lactation or i n t he contraceptive p i ll 
(Daniel et al, 1967; Jeffcoate e t a l , 1 968; Polle r and Thomson, 
1966; Poller et al, 1969; Swyer, 1966; Vessey and Doll, 1968, 
1969). 
There is no direct evidence to suggest a carcinogenic 
effect of oestrogen. Cases have been reported i n whi ch 
prolonged administration has co i nci ded wi th the development 
of uterine or breast carcinoma and t h i s aspect i s f u l l y r eviewed 
by Rogers (1956b) and Larson (1954 ). It i s poss i b l e to s t ate 
that in this respect the concer n over t he use of oestrogens 
does not seem justified by a revi ew of the available evidence . 
PART 2 
OBJECTIVES OF THE PRESENT STUDY 
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2. OBJECTIVES OF THE PRESENT STUDY 
The present investigati on was undertaken i n o r der to clarify 
the clinical and metabolic effects of the menopause following 
bilateral oophorectomy and to evaluate the role of replacement 
exogenous oestrogen therapy. To this end t he following studies 
were carried out: 
1. A study of · thedlinical effects directly r elated to ovarian 
oestrogen withdrawal fol l owing b ilateral oophorectomy. 
2. To determine, should any c linical effects be found, whether 
such effects could be reversed by exogenous oestr ogen 
replacement therapy. 
3. A study of the changes in vaginal smear followi ng bilateral 
oophorectomy and subsequent oestrogen therapy . 
4. A study of the changes in plasma cholesterol i n patients 
undergoing bilateral oophorectomy and the effect of 
administration of exogenous oestrogen in these patients. 
5. A study of the effect of bilateral oophorectomy on plasma 
calcium, phosphorus and alkal i ne phosphatase values and the 
result of subsequent exogenous oestrogen therapy to the 
same group of patients. 
6. A consideration of the clinical and metabolic effects of 
bilateral oophorectomy with particul ar r e f erence to the 
place of this procedure in gynaecology at the time of 
routine abdominal hysterectomy for benign conditions; and to 
consider further the role of exogenous oestrogen replacement 
therapy in all females after the menopause . 
7. A controlled comparative evaluati on of two d ifferent forms 
of commercially available oestrogen and a p l acebo. 
~1 
PART 3 
MATERIALS AND METHODS 
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3.1 MATERIAL 
The principal aims of the study required a detailed clinical 
history and examination and the collection of material from 
varying groups of women whose samples would reflect an 
average physiological status for the group in question. The 
acquisition of this comprehensive material on sufficient patients 
and on repeated occasions over a period of one year for each 
patient posed a difficult organizational problem. Accordingly, 
a special 'Menopause Clinic' was established in the Outpatient 
Department of the Groote Schuur Hospital, Cape Town. This was 
conducted at a - regular time each week for two years. The study 
comprised inpatients gathered for follow-up and outpatients who 
were recalled following a survey of the records of the Department 
of Gynaecology. Many persons and samples had subsequently to be 
excluded owing to incomplete follow up or attendance or failure 
to fulfil the criteria listed below . As far as possible, however, 
patients, once entered into the study, were persuaded from 
defaulting. 
The number of patients who were studied in the course of 
the investigations described in this thesis is such as to render 
it unpractical to include individual case reports . However, 
patients were gathered in several groups according to the 
following criteria : 
Points of similarity 
1. Females aged 45 to 55 
2. Absence of gynaecological or other diagnosed malignancy 
3. Absence of vaginal treatment in the preceding 2 months 
prior to the first visit 
4. They had not received hormonal, vitamin or digitalis therapy 
in the preceding 6 months 
5. There were no symptoms of general disease 











Premenopausal - i n tact u t erus and ov ar i es 
Premenopausal - investigation c ommenced 
immediate l y pos t oophor e ctomy 
Premenopausal - i nves tigation c ommenced 
6 months pos t oophorectomy 
Premenopausal - i n vestigat ion commenced 
2 years post oophor e ctomy 
Postmenopausal - i nv estigat ion commenced 
immediately p o s t oophor ectomy 
Contro l - 6 mo n ths post hyster ect omy wi th 
conserved ovaries 
Control - 2 y e ars post nys terect omy with 
conserved ov aries 
The ultimate number of patient s comp l e tely s t udi ed was 
85, divided into two ma j o r s ub-gro ps . The fir s t g roup 
comprised 50 patients (g r oup s 2 1 3, 4 and 5 ) who f orme d t h e 
detailed material for s tudy and were thu s investigat ed and 
treated on 6 occasions eac h . The second group of 35 pa tients 
(groups 1, 6 and 7) was s een and invest · gated on one vis i t 
for control purposes on l y 
The 85 patients were d ivided b e ween h e mi nor sub-groups 
as follows 
GROUP NO. DESCRIPTION NO . OF PATIENTS 
1 Norma l p r emenop ausal 9 
2 Premenopausal in estigated 
immedi atel y post oophore ctomy 14 .. 
3 Premenopausal investigated 6 
months pos t oophorectomy 13 
4 Premenopaus a l investigated 2 50 
years pos t oophorectomy 18 
5 Postmenopausal inves tiga ted 
immediate l y post oophorectomy 5 "' 
6 6 months pos t hysterectomy 
wi th conser ved ovaries 8 
7 2 years pos t hyste r e ctomy 
with conserved ovaries 18 
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It will be observed that all pat.ients to receive 
treatment (Groups 2, 3, 4 and 5 ) had undergone 
oophorectomy. The post-oophorectomy groups were selected 
for detailed study because the climacteric cannot be 
accurately timed. Hence it is virtually impossible to 
collect a study group of human ma eri a l at an accurately 
timed menopause other than in t h is way . Thus 
evaluation of oophorectomized pati ents a lows of 
precise analysis of features related to ovarian oestrogen 
withdrawal. 
At first inspection the number of patients i n 
each sub~group appears small . It. was not possib e t o 
enlarge the size of the groups 1.n the time availab l e as 
the patients investigated comprise the total c inical 
material obeying the criteria for selection and 
passing through Groote Schuur Hospital at the time 
of this investigation . 
Allowance has therefore been made for this in 
the statistical evaluation . 
The figures shown above excluded inves igation of 
the several patients who failed to attend for the 
full scheme of treatment . In a 1 instances except o~e 
the reason related to departure from Cape Town . One 
patient, however, died between the 5th and last visit. 
The cause of death was descr ibed at post-mortem as 
being due to 
"Faecal peritonitis, perforation at the caecal-
colonic junction and multiple peritoneal and 
pelvic adhesions" . 
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The data obtained for this patient was included in 
the final analysis. Data for the other patients i n 
Groups 2, 3, 4 and 5 attending on less than 5 of the 6 
required visits was excluded on the grounds of be i ng 
incomplete. 
3.2 . METHODS 
3.2 . 1 GENERAL 
All patients studied had the same history, exami nat i on 
and investigations performed at each visit. Accordingly, 
it was possible to establish a set protocol or tria l 
form. In view of the anticipated amount of data that was 
to be collected, this form was drafted at the outset of 
the trial to allow for computer analys i s. Slight al t erations 
that occurred during the study necessitated revi sion o f 
the form. 
The trial form lists symptoms, s i gns and investi gations 
that were assessed. The mode of assessment or translation 
to a numerical measurement is explained by the code sheet 
(Trial form and explanatory code - see Appendix A). 
After completion of the study all data was transferred 
on to IBM 80-line computer punch cards for subsequent 
analysis and statistical evaluation through an IBM 1130 
computer. 
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3.2.2. CLINICAL EVALUATION 
Details of symptomatology and changes in clinical signs 
were determined according to accepted clinical criteria. 
Symptoms, for the purpose of comparison,were graded as 
being absent, slight, moderate or severe. The development of 
the breasts was assessed as being of the firm, rounded type of 
reproductive years or else of atrophic, flabby postmenopausal 
type. 
A full-face colour photograph was taken of all patients 
in groups 2,3,4 and 5 at each visit to the clinic . The purpose 
of this procedure was to record any change in facial features, 
wrinkling of skin, scalp hair-line configuration or facial hair . 
The inclusion in this thesis of prints of the hundreds of 
photographs taken during the course of this study was impractical. 
Thus, reference to the results of this investigation will be 
incorporated in Part 5.1 only . 
Further details of actual symptoms and signs measured are 
reflected and listed in the trial sheet and explanatory code 
(Appendix A) • 
It is necessary to comment on factors 74 (overall impression), 
' l 
79 (patient's assessment) and 80 (husband's assessment). These 
were scores determined at each visit following the completion of 
history taking, clinical examination and collection of samples 
for investigation and applied to all patients receiving therapy 
(i.e. groups 2~ 3, 4 and 5). The patient was asked how she felt 
generally and specifically how she felt in comparison to the 
previous visit. Factors taken into account were as follows : 
1 . Degree of general feeling of 'well-being' and interest in life 
2. General ability to perform a full day's work, i.e. degree 
of fatigue in response to work 
3. Whether side effects of therapy detracted from any possible 
beneficial effects 
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4. Ability to maintain sati sfact ory i nter-personal relationsh ips 
without excessive irrit ability, anxi ety, impatience, etc. 
The above factors were bal anced i n t o an overall i mpression 
and awarded a score as fo l lows : 
1 = marked i mprovement 
2 = sl i ght i mprovement 
3 = unchanged 
4 = s light de t e rioration 
5 = marked de t er i oration 
The husband's assessment was d i sconti nued early in the study 
due to the high incidence of d i vor cees, wi dows and disinterested 
husbands. 
It is conceded that an 'impr ess i on' is not a scientific 
measurement. Nevertheless, all patients were assessed by t he 
author only and points awarded as far as i s humanly poss i b l e 
without bias. 
The value of this assessment i s cons i dered to be pur ely a 
measurement of euphoria or eff ect on t he mental s t ate of the 
patient, produced either as a drug response or the result of 
physician's care (placebo effect ) . No similar measurement 
appears to have been attempted previ ous l y . Nevertheless, despite 
the wid~ margin of error poss i ble, t h i s evaluation was considered 
to be both necessary and of potential va l ue in tes t ing claims 
for the 'tonic effect' of long-t erm oes t rogen therapy, as 
discussed under section 1 . 6 
3.2.3 METHODS FOR THE DETERMINATION OF BLOOD CHOLESTEROL, 
CALCIUM, PHOSPHORUS AND ALKALINE PHOSPHATASE VALUES 
Cholesterol, calci um, i norgani c p hosphorus and alkaline 
phosphatase values were determi ned by standard methods in the 
Department of Chemical Pathology, Uni vers i ty of Cape Town . 
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Cholesterol : The procedure followed in the Department of 
Chemical Pathology for the determination of cholesterol in serum 
is described by Pearson, Stern and McGarack (1953 ) and has been 
slightly modified by Duncan (1959). Results are presented in 
mg per 100 ml. Normal values by this method are 150 - 250 mg 
per 100 ml. 
Calcium Plasma calcium values were determined by high atomic 
absorption spectrophotometry. Results are presented in mg per 
100 ml. Normal values for this laboratory are 8.5 to 10.6 mg 
per 100 ml. 
Inorganic phosphorus : Phosphorus values were determined by 
the standard clinical method of Fiske and Subarrow {1929). 
Results are presented in mg per 100 ml, the normal v~~ues 
ranging between 2.8 and 4.5. 
Alkaline phosphatase Alkaline phosphatase was determined on 
the Auto-Analyser using phenolphthalene monophosphate a s 
substrate with results corrected to Bodansky-Reinhart units. 
The normal value for this laboratory is less than 12 Bodansky-
Reinhart units. 
3.2.4 VAGINAL SMEAR 
This aspect of the investigation was personally conducted 
in the Cytology Laboratory of the Department of Gynaecology 
with the assistance of one technician. 
The smears were taken with a wooden spatula from the lateral 
fornix. Care was taken to avoid traumatisation of the epithelium. 
The inclusion of cells from the outer part of the genitals 
was prevented by using a speculum. The material obtained 
was spread gently, without rubbing, on a glass slide. The 
sli de was immediately sprayed with an aerosol-type fixative 
consisting of normal propyl alcohol, polyethylene glycols 400 and 
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1500, trichloro-monofluro-methane frion 11) and dichloro-
difluro-methane (frion 12). The fixation time varied from one 
hour to two days. 
Vaginal smears were stained by the method of Papanicolaou 
and Traut (1943). 
There is a diversity of terms and definitions used for the 
cells that have desquamated from the squamous epithelium. 
These are reviewed by Gr~nroos (1965) and Wied (1968). The 
definitions in this study were as follows 
(i) Parabasal cells were determined on a basis of cellular 
size, the limits being a di.ameter of 15 - 30 p, and shape, 
the cells demonstrating a round or oval circumference with 
no angulation. 
(ii) Intermediate cells were identified as squamous cells 
presenting a definite differentiation of cytoplasm, a 
beginning retraction of the nuclear diameter, but without 
complete karyopknosis (International Academy of 
Gynaecological Cytology, 1958). 
(iii) Superficial cells were distinguished from other cells 
above all by their pyknotic nucleus. In this study a 
pyknotic nucleus was defined as one which does not exceed 
5.5 pin diameter and appears black and structureless 
(de Neef, 1967; Gr~nroos, 1965; Hindman et al, 1962; 
Wachtel, 1964). 
The counting of cells was performed as follows. Under a 
low magnification (8 x 10) and in a bright field a clear area 
was selected containing separate epithelial elements. A total 
of 500 cells was identified and counted in vertical and 
horizontal directions under a magnification of 8 x ocular and 
45 x objective. The size of the pyknotic nucleus was 
measured at the same time with an ocular micrometer. Cells 
that were too degenerated or too clumped were not included. 
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The number of parabasal, intermediate and superficial 
cells were corrected to percentages and placed in that order 
e.g. 7 : 63 : 30. The Maturation Index (Frost, 1958 ) 
thus obtained allowed for easy transfer to the computer for 
statistical evaluation. 
3 . 2.5 TREATMENT PROGRAMME 
The 50 patients comprising groups 2, 3, 4 and 5 were 
each evaluated on 6 occasions over a period of one year. On 
each visit all investigations were repeated before treatment 








DRUG ADMINISTERED AFTER 
INVESTIGATION COMPLETED 
Oestradiol valerate 4 mg daily 
Oestradiol valerate 4 mg daily 
Oestradiol valerate 4 mg daily 
Oestradiol valerate 4 mg daily 
Placebo - Single blind 
Conjugated equine oestrogen 
5 mg daily 







Thus the data obtained on each visit was a reflection 
of the following status 
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VISIT NO. DESCRIPTION 
1 Control - variabl e time post oophorectomy 
2 1 month conti nuous oestradi ol valerate 
therapy 
3 3 months continuous oestradiol valerate 
therapy 
4 6 months continuous oestradiol valerate 
therapy 
5 3 months continuous p l acebo therapy -
single blind 
6 3 months conjugated equi ne oestrogen 
therapy 
No results for visit 2 1 month conti nuous oestradiol 
valerate therapylare presented i n this thesis. This visit was 
essentially an early check to de t ermi ne t hat patients were tak i ng 
therapy as prescribed. 
The substitution of placebo for oestradiol valerate was 
performed on a single blind bas i s . The tablets were identical 
in appearance and the patients were kept uninformed of the 
substitution. Unfortunately it was not possible to have an 
identical type tablet of conjugated equine oestrogen. Following 
the substitution at visit 5 the patients were informed that the 
hormone was the same but the processing of the tablet was of a 
different nature. In the majority of instances this was 
accepted without comment. In all i nstances the drugs were 
administered continuously with no cycl i cal variation. 
The choice of oestrogens used was dec i ded in view of their 
both being described as natural oestrogens (Manufacturers' 
information) 
Oestradiol valerate (Progynova, Schering) is a fatty acid 
ester of the naturally occurring foilicular hormone oestradiol 
and, parenterally administered i n animals, has an , oestrogenic 
effect of similar potency to that of oestradiol. The valeric 
acid ester is excreted via the lungs. Orally administered, 
60 mg of oestradiol valerate is sufficient to achieve full 
endometrial proliferation in a female castrate. 
(Manufacturers' information - Schering A.G., Berlin) 
Conjugated equine oestrogens (Premarin, Ayerst) are water 
soluble oestrogens derived from pregnant mares' urine. They 
comprise oestrone sulphate (over 70% ) , equilin sulphate, 
3-monosulphate of oestradiol - 17a, 3-monosulphate of 
dihydroequilenin - 17a and other conjugated steroids~ The 
proliferative dose is 80 mg (Manufacturers' information -
Ayerst Laboratories, New York). 
The dosage selected was related to the proliferative dose 
as follows : 
Proliferative dose of Oestradiol valerate = 60 ·mg 
Proliferative dose of Conjugated oestrogens= 80 mg 
Hence by calculation a dose of 4 mg of oestradi ol valerate 
was considered to be equivalent to 5 mg of conjugated equine 
oestrogens for the evaluation of other oestrogenic effects. 
3.2 . 6 STATISTICAL ANALYSIS 
All data was analysed through an IBM 1130 computer with the 
assistance of a computer programmer and statistician (see 
ACKNOWLEDGEMENTS)· 
The statistical tests applied were basically the student t 
distribution to pure measurements (e.g. weight, cholesterol, 
calcium , phosphorus and alkaline phosphatase ) and the chi 
square distribution test to clinical features (e.g. hot flushes, 
headache, irritability, etc.) 
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In this study the differences or correlations are considered 
statistically almost significant if p c:::.0.05, significant if 
Pc:::::0.01 and highly significant if p==:0.001. 
For the purpose of completeness of presentation, comparisons 
between all study groups for statistical significance are listed 
under the individual headings of Part 4 - RESULTS. As all 
comparisons may not be of importance for any one parameter, only 
the relevant comparisons will be commented on in the accompanying 
text to each table. 
3.2.7 NOTE ON DISCONTINUED INVESTIGATIONS 
Two investigations were discontinued early in the course 
of this study : 
1. Glucose tolerance test; This investigation was discontinued 
because most patients were loath to submit themselves to 
this procedure for as many as six times in one year. Analysis 
of the results that were obtained was of small value and 
such results have accordingly been excluded from this thesis. 
2. Radiographs of lwnbar spine X-rays of the lumbar spine 
were taken at every patient's first visit and repeat 
radiographs were taken on several occasions in some instances. 
This procedure, however, was found to be valueless for the 
accurate assessment of osteoporosis and, as the emphasis 





4.1 ANALYSIS OF SYMPTOMS 
4.1 . 1 HOT FLUSHES 
The overall incidence and degree of severity of hot flushes 
.,.,,.---
in all groups of patients studied is shown in Tables I and 2 . 
The response of hot flushes in oophorectomized females to 
oestrogen and placebo therapy is outlined in Table 2. 
The statistical comparison between the groups of patients 
investigated and the overall incidence of hot flushes of all 
degrees of severity is tabulated in Table 3 . 
There is a low incidence of hot flushes i n the normal 
premenopausal group (11.1%) and the groups of patients 
undergoing hysterectomy with conservation of ovaries 
(12.5% at 6 months and 16.7% at 2 years). These results also 
suggest that the incidence of hot flushes does not signifi cantly 
increase for at least 2 years after such surgery, i.e. the 
conserved ovaries continue to function for at least 2 year s . 
Following oophorectomy there is a highly significant 
increase in the incidence of this symptom ( p c::::: O. 001) . The 
incidence is increased 6 months after oophorectomy . (p < o. 01) , 
but does settle slightly at the 2 year mark (p <0.01). 
Comparison of the oophorectomized to the non-oophorectomized 
groups reveals highly significant differences (p <0.001). 
Retention of ovaries decreases the likelihood of the development 
of hot flushes. 
The response of hot flushes to oestrogen administration 
is striking (p <0.001) with relief of the symptom i n the 
majority of patients. This cure is not a placebo effect as 
single blind cress-over to placebo results in return of the 
symptoms in a high proportion of cases (66%) and this finding 
is highly significant (p <0.001). 
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Both forms of oestrogen used in this study were effective 
(p <0.001) and no statistical difference in effect between 
the two hormones could be demonstrated. 
Thus the symptom of hot flushes has been shown to be oestrogen 
dependent - oophorectomy results in a striking increase in the 
incidence of hot flushes and oestrogen therapy significantly 


















































































































































































































































































































































































































































































































































































































































































































































































































































































EXPLAtlATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy (i.e. Groups 2+3+4+5) 
Control - variable time< 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 3 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED AND THE OVERALL INCIDENCE (ALL DEGREES OF 




































GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
OVERALL GROUP OVERALL P< 
INCIDENCE OF NO. INCIDENCE OF 
HOT FLUSHES HOT FLUSHES 
PER DAY PER DAY 
11 . l 2 50 . 0 0.001 
11.1 3 100 . 0 0.001 
11.1 4 61.2 0.001 
11.1 5 60 . 0 0.01 
11.1 6 12.5 .. 
11.1 7 16.7 .. 
50 . 0 3 100 . 0 0.01 
50.0 4 61 . 2 . . 
50 . 0 5 60 . 0 .. 
50 . 0 6 12.5 0.01 
50.0 7 16.7 0.01 
100 . 0 4 61.2 0.01 
100.0 5 60.0 0.-01 
100.0 6 12.5 0.001 
100.0 7 16.7 0.001 
61 . 2 5 60 . 0 .. 
61 . 2 6 12.5 0.001 
61.2 7 16.7 0.001 
60 . 0 6 12 . 5 0.001 
60.0 7 16 .7 0.001 
12 . 5 7 16.7 . . 
68.0 8 B 6 . 0 0.001 
68 . 0 8 C 10.0 0.001 
68.0 8 D 66.0 . . 
68 . 0 8 E 14.3 0.001 
6 .o 8 C 10 . 0 .. 
6.0 8 D 66.0 0.001 
6.0 8 E 14.3 .. 
10.0 8 D 66.0 0.001 
10.0 8 E 14.3 .. 
66 . 0 8 E 14 .3 0.001 
1. See opposite page for explanatory code 
of group nwnbers 
2. The symbol . • means statistically insignificant 
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4.1.2 CLINICAL ATROPHIC VAGINITIS 
The incidence of clinical or symptomatic atrophic vaginitis 
as determined by pain, blood-stained vaginal discharge or 
dyspareunia, was · low. Despite this, a definite relationship 
(p <0.001) between oestrogen administration and 
disappearance of symptomatic atrophic vaginitis exists 
(Table 4). Atrophic vaginitis was present in 20% of the 
group of 50 oophorectomized patients when first seen. Three 
months' oestradiol valerate therapy reduced this incidence to 
4% and at 6 months there were no patients with clinical 
atrophic vaginitis. This finding correlates we l l with the 
























































































































































































































































































































































The number and incidence of patients complaining of headache 
is shown i-n Tables 5 and 6. The response of the oophorectomized 
females in terms of relief of headache following oestrogen and 
placebo therapy is summarised in Table 6. The statistical 
comparison for any significant difference in the incidence of 
headache of all degrees of severity between the various groups 
of patients investigated is outlined in Table 7. 
No significant relationship has been demonstrated between 
the incidence of headache and menopause or removal of ovaries. 
Thus the incidence of patients complaining of headache was 
similar in the premenopausal group (22.2%) and the group of 
patients having undergone oophorectomy (22.0%). 
The results in the groups investigated after hysterectomy 
with conservation of ovaries are somewhat incongruous (12.5% at 
6 months and 50% at 2 years). The higher incidence i n the 
2 year group is of possible statistical significance (p < 0.05). 
Oestradiol valerate administration (Table 6) did not decrease 
the incidence of this symptom and there was no placebo effect. 
Administration of conjugated oestrogen after placebo reduced 
the incidence of headache from 32.0% to 14.3% but this was 
only of possible significance (p <0.05). In this respect, 
therefore, the effect of conjugated equine oestrogen was 
possibly superior to that of oestradiol valerate (p <0.05). 
Headache is thus shown to be a symptom unrelated to 



































































































































































































































































































































































































































































































































































































































































































































































































































































EXPLAUATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy (i.e. Groups 2+3+4+5) 
Control - variable time< 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 7 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED AND THE OVERALL INCIDENCE (ALL DEGREES OF 




































GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
OVERALL GROUP OVERALL P< 
INCIDENCE OF NO. INCIDENCE OF 
HEADACHE HEADACHE 
22.2 2 21.4 .. 
22.2 3 15.4 .. 
22 . 2 4 27.8 .. 
22.2 5 20.0 . . 
22.2 6 12.5 .. 
22.2 7 50.0 0.05 
21.4 3 15.4 .. 
21.4 4 27.8 .. 
21.4 5 20.0 .. 
21.4 6 12.5 .. 
21 . 4 7 50.0 0.05 
15.4 4 27.8 .. 
15.4 5 20 . 0 . . 
15 . 4 6 12.5 .. 
15.4 7 50.0 0.01 
27.8 5 20.0 .. 
27.8 6 12.5 .. 
27.8 7 50.0 0.05 
20.0 6 12.5 .. 
20.0 7 50.0 0.05 
12.5 7 50.0 0.01 
22.0 8 B 24.0 .. 
22.0 8 C 28.0 .. 
22.0 8 D 32.0 .. 
22.0 8 E 14.3 .. 
24.0 8 C 2.8. 0 .. 
24.0 8 D 32.0 .. 
24.0 8 E 14.3 .. 
28.0 8 D 32.0 .. 
28.0 8 E 14.3 0.05 
32.0 8 E 14.3 0.05 
See opposite page for explanatory code 
of group numbers 
The symbol means statisticaliy in$ignificant 
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4.1.4. PALPITATIONS 
The incidence of palpitations in all the groups studied 
is shown in Tables 8 and 9. The response of oophorectomized 
females to oestrogen and placebo therapy is also listed in 
Table 9. Table 10 summarises the statistical comparison 
between the groups of patients investigated in terms of the 
incidence of palpitations. 
No premenopausal patients complained of palpitations. 
The incidence of this symptom was similar (20% to 38.9%) in 
all the other groups of patients prior to any treatment. 
Thus oophorectomy is not shown to result in an increased 
incidence of palpitations. 
The response of the oophorectomized group of patients to 
treatment was of possible significance. Oestradiol valerate 
therapy reduced the incidence of palpitations from 30.0% to 
14.0% (p <0.05) over a period of 6 months. However, single-
blind crossover to placebo therapy resulted in a further drop 
in this incidence to 8.0% and the subsequent cross-over to 
conjugated oestrogen therapy showed no significant change. 
The overall interpretation of this behaviour, despite the low 
degree of stati$tical significance, is that the response of this 
symptom to treatment is purely a placebo effect. 
Hence oestrogen deprivation following bilateral oophorectomy 
did not result in an increased incidence of palpitations; 
similarly, exogenous oestrogen administration per se was of 




































































































































































































































































































































































































































































































































































































































































































































































































































' EXPLAtlATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy (i.e. Groups 2+3+4+5) 
Control - variable time< 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 10 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED AND THE OVERALL INCIDENCE (ALL DEGREES OF 



































GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
OVERALL GROUP OVERALL P< 
INCIDENCE OF NO. INCIDENCE OF 
PALPITATIONS PALPITATIONS 
0 2 21.4 0.001 
0 3 30.8 0.001 
0 4 38.9 0.001 
0 5 20.0 0.01 
0 6 25.0 0.001 
0 7 22.2 0.001 
21.4 3 30.8 .. 
21.4 4 38.9 . ~ 
21.4 5 20.0 . . 
21 .4 6 25.0 .. 
21 . 4 7 22.2 . . 
30 . 8 4 38.9 .. 
30.8 5 20.0 . . 
30.8 6 25.0 .. 
30.8 7 22.2 . . 
38.9 5 20.0 .. 
38.9 6 25.0 . . 
38 .9 7 22.2 .. 
20.0 6 25.0 .. 
20.0 7 22.2 .. 
25.0 7 22.2 . . 
30.0 8 B 18.0 0.05 
30.0 8 C 14.0 0.05 
30.0 8 D 8.0 0.05 
30.0 8 E 10.2 0.05 
18.0 8 C 14.0 . . 
18.0 8 D 8 .o .. 
18.0 8 E 10.2 .. 
14 . 0 8 D 8.0 .. 
14.0 8 E 10.2 . . 
8 . 0 8 E 10.2 . . 
1. See opposite page for explanatory code 
of group numbers 
2. The symbol •. means statistically insignificant 
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· 4.1.5 ANGINA PECTORIS 
The number and incidence of patients complaining of angina 
pectoris is outlined in Tables 11 and 12. The effect of 
oestrogen and placebo therapy on oophorectomized patients is shown 
in Table 12. The statistical comparison of the incidence of 
angina pectoris between the various groups investigated is 
summarised in Table 13. 
Angina pectoris becomes a significant complaint after 
the procedure of bilateral oophorectomy in the premenopausal 
female (p <:0.001) (See Table 13). Oaphorectomy performed on 
the postmenopausal female does not significantly affect the 
incidence of this symptom in comparison with the normal 
premenopausal group of patients. Conservation of ovaries 
protects against the development of angina pectoris in both 
the 6 month groups (p ,<0.001) and the 2 year groups (p ,<0 . 001) . 
The response of angina pectoris to oestrogen and placebo 
therapy is similar to that described for palpitations under 
Section 4.1.4. Thus the slight response to therapy indicates 
a placebo ef°fect only. 
Angina pectoris is thus shown to be a symptom related to 
oophorectomy but unrelieved by oestrogen therapy. Nevertheless, 

























































































































































































































































































































































































































































































































































































































































































































































EXPLAtlATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy ti.e. Groups 2+3+4+5) 
Control - variable time < 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 13 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED AND THE OVERALL INCIDENCE OF ANGINA PECTORIS 



































GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
OVERALL GROUP OVERALL P< 
INCIDENCE OF NO. INCIDENCE OF 
ANGINA ANGINA 
PECTORIS PECTORIS 
0 2 14.3 0.01 
0 3 30.8 0.001 
0 4 27.8 0.001 
0 5 0 .. 
0 6 0 .. 
0 7 0 . . 
14.3 3 30.8 .. 
14.3 4 27.8 .. 
14.3 5 0 0.01 
14.3 6 0 0.01 
14.3 7 0 0.01 
30 . 8 4 27.8 
h ·:001 30.8 5 0 
30.8 6 0 -t O. 001 
30.8 7 0 0.001 
27.8 5 0 0.001 
27.8 6 0 0.001 
27 . 8 7 0 0.001 
0 6 0 .. 
0 7 0 .. 
0 7 0 
"' 
. . 
22.0 8 B 12.0 .. 
22.0 8 C 8.0 0.05 
22.0 8 D 8.0 0.05 
22.0 8 E 4.1 o.os 
12.0 8 C 8.0 . . 
12.0 8 D 8.0 .. 
12.0 8 E 4.1 .. 
8.0 8 D 8.0 . . 
8.0 8 E 4.1 . . 
8.0 8 E 4.1 .. 
1. See opposite page for explanatory code 
of group numbers 




The number and incidence of patients complaining of insomnia 
is outlined in Tables 14 and 15. The effect of oestrogen and 
placebo therapy on insomnia in oophorectomized females is shown 
in Table 15. The statistical comparison between the groups 
studied for the significance of the incidence of insomnia is 
summarised in Table 16. 
Insomnia is shown to be a common symptom in all groups 
of patients except the normal premenopausal group. There is 
only a possible statistical difference between the oophorectomized 
and non-oophorectomized patients p ·<:0.05). It is thus not 
possible to draw any conclusions in this respect. 
However, the oophorectomized groups receiving oestrogen 
and placebo therapy show a highly significant response to 
treatment. The effect of treatment is a placebo one similar 
to that described under section 4.1.4, but of much greater 
statistical significance. Oestradiol valerate therapy for 6 
months results in a reduction of the incidence of insomnia 
from 52.0% to 26.0% (p <:0.01). Single blind cross-over to 
placebo therapy and subsequent cross-over to conjugated oestrogens 

































































































































































































































































































































































































































































































































































































































































































































































EXPLArlATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy t i.e. Groups 2+3+4+5) 
Control - variable time< 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 16 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED AND THE OVERALL INCIDENCE OF INSOMNIA 
FOR SIGNIFICANT DIFFERENCES 
GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
GROUP OVERALL GROUP OVERALL P< 
NO . INCIDENCE OF NO. INCIDENCE OF 
INSOMNIA INSOMNIA 
1 0 2 50.0 0.001 
1 0 3 61.5 0.001 
1 0 4 44.4 0.001 
1 0 5 60.0 0.001 
1 0 6 25.0 0.001 
1 0 7 33.3 0.001 
2 50 . 0 3 61.5 . . 
2 50.0 4 44.4 . . 
2 50.0 5 60.0 . . 
2 50 . 0 6 25.0 0.05 
2 50.0 7 33.3 0.05 
3 61 .5 4 44.4 . . 
3 61.5 5 60.0 . . 
3 61.5 6 25.0 0.01 
3 61.5 7 33.3 0.01 
4 44.4 5 60.0 .. 
4 44 . 4 6 25.0 0.05 
4 44 . 4 7 33.3 . . 
5 60.0 6 25.0 0.01 
5 60.0 7 33 . 3 0.05 
6 25 . 0 7 33.3 .. 
8 A 52.0 8 B 18.0 · 0.001 
8 A 52.0 8 C 26.0 0.01 
8 A 52.0 8 D 18.0 0.001 
8 A 52.0 8 E 12.2 0.001 
8 B 18. O 8 C 26.0 . . 
8 B 18.0 8 D 18.0 . . 
8 B 18.0 8 E 12.2 . . 
8 C 26.0 8 D 18.0 .. 
8 C 26.0 8 E 12.2 0.05 
8 D 18 . 0 8 E 12.2 .. 
NOTE: 1 . See opposite page for explanatory code 
of group numbers 





The number and incidence of patients complaining of 
irritability is shown in Tables 17 and 18. The effect of oestrogen 
and placebo therapy on irritability in oophorectomized females 
is listed in Table 17. The statistical comparison between the 
groups studied for significant differences in the incidence of 
irritability is summarised in Table 19. 
It is clearly shown that irritability is not an effect of 
bilateral oophorec_tomy . No significant relationship exists 
between ' any of the oophorectomized and non-oophorectomized 
groups. 
Oestrogen and placebo therapy to oophorectomized females 
have essentially a placebo effect on the symptom of irritability, 
as explained under Section 4.1.4. 
However, conjugated oestrogen therapy did produce more than 
just a placebo effect . Comparison of the control group of 
oophorectomized females to the conjugated oestrogen treated 
group showed incidences of 38.0% and 8.2% respectively (p <:0.01). 
Comparison of the 3 month oestradiol valerate group to the 3 month 
conjugated oestrogen group showed this difference still to be of 
'possi-bL~=.-significance (p < 0.05) and this relationship is again 
confirmed by comparing placebo therapy to conjugated oestrogen 
therapy (.p < o. 05 ) • 
The conclusion to be drawn from these findings is that 
irritability is not a response of oophorectomy and is relieved 
essentially by placebo therapy. The fact that conjugated 
oestrogens have some ability to relieve this symptom may be 
related to other effects of conjugated oestrogen, notably the 


























































































































































































































































































































































































































































































































































































































































































































































































































































EXPLANATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausa l , investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postrnenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy ( i.e. Groups 2+3+4+5) 
Control - variable time< 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 19 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED AND THE OVERALL INCIDENCE (ALL DEGREES OF 



































GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
OVERALL GROUP OVERALL P< 
INCIDENCE OF NO. INCIDENCE OF 
IRRITABILITY IRRITABILITY 
33.3 2 35 .6 .. 
33.3 3 38.5 .. 
33.3 4 33.3 . . 
33.3 5 60.0 0.05 
33 . 3 6 37.5 .. 
33 . 3 7 27.8 .. 
35.6 3 38.5 . . 
35.6 4 33.3 . . 
35.6 5 60.0 0.05 
35.6 6 37.5 .. 
35.6 7 27.8 .. 
38.5 4 33.3 . . 
38.5 5 60.0 .. 
38.5 6 37.5 .. 
38.5 7 27.8 . . 
33.3 5 60.0 0.05 
33.3 6 37.5 . . 
33.3 7 27.8 .. 
60 . 0 6 37.5 . . 
60 . 0 7 27.8 0.01 
37 . 5 7 27.8 . . 
38.0 8 B 20.0 0.05 
38.0 8 C 20.0 0.05 
38.0 8 D 22.0 0.05 
38.0 8 E 8.2 0.01 
20.0 8 C 20.0 . . 
20.0 8 D 22 . 0 .. 
20.0 8 E 8.2 0.05 
20.0 8 D 22.0 . .. 
20.0 8 E 8.2 0.05 
22.0 8 E 8.2 0.05 
1. See opposite page for explanatory code 
of group numbers 





The number and incidence of patients affected by depression 
in the various groups investigated is shown in Tables 20 and 21. 
The effect of oestrogen and placebo therapy on depression in 
oophorectomized females is also shown in Table 21. The 
statistical comparison for significant differences between the 
groups studied in the incidence of depression is summarised 
in Table 22. 
Oophorectomy appears to result in a proportion of patients 
developing depression, although the results generally are of 
possible statistical significance only .. The premenopausal and 
non-oophorectomized groups presented an overall incidence of 
depression of 22.2% and 37.5%. , The incidence ranged from 
46.2% to 64.3% in the four post-oophorectomy groups studied. 
Oestrogen and placebo therapy produced a statistically 
\ 
highly significant response (p <:0.001). The control post-
oophorectomy group had an overall incidence of depression of 
56.0%. Oestradiol valerate therapy reduced the incidence to 
30. 0% at 3 months (p <: O. 01) and to 24. 0% at 6 months p < O. 01) • 
Single blind cross-over to placebo further reduced this incidence 
to 20.0% (p <:0.001) and the final cross-over to conjugated 
oestrogen resulted in a further drop to 10.2% (p <:0.001). This 
progressive fall in incidence of depression through the year 
of treatment can be explained on a placebo basis. 
These observations seem to indicate that the operation of 
oophorectomy results in a significant incidence of depression 
which apparently develops on a psychological basis as demonstrated 





















































































































































































































































































































































































































































































































































































































































































































































































































EXPLANATION OF GROUP NUMBERS DESCRIBED 
lN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy (i. e. Groups 2+3+4+5) 
Control - variable time< 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 22 
ST.ATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED AND THE OVERALL INCIDENCE (ALL DEGREES OF 
SEVERITY) OF DEPRESSION FOR SIGNIFICANT DIFFERENCES 
GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
GROUP OVERALL GROUP OVERALL P< 
NO . INCIDENCE OF NO. INCIDENCE OF 
DEPRESSION DEPRESSION 
1 22 . 2 2 64 . 3 0.01 
1 22.2 3 46.2 0.05 
1 22.2 4 55 . 5 0.01 
1 22.2 5 60.0 0.01 
l 22 . 2 6 37.5 .. 
1 22.2 7 33.4 .. 
2 64.3 3 46.2 .. 
2 64.3 4 55.5 .. 
2 64.3 5 60.0 .. 
2 64.3 6 37.5 0.05 
2 64.3 7 33.4 0.05 
3 46 . 2 4 55.5 .. 
3 46.2 5 60.0 .. 
3 46.2 6 37.5 . . 
3 46 . 2 7 33.4 .. 
4 55.5 5 60.0 .. 
4 55 . 5 6 37.5 .. 
4 55.5 7 33.4 0.05 
5 60 . 0 6 37.5 0.05 
5 60.0 7 33.4 0.05 
6 37.5 7 33.4 . . 
8 A 56.0 8 B 30.0 0.01 
8 A 56 . 0 8 C 24 . 0 0.01 
8 A 56.0 8 D 20.0 0.001 
8 A 56.0 8 E 10.2 0.001 
8 B 30.0 8 C 24.0 .. 
8 B 30.0 8 D 20.0 .. 
8 B 30.0 8 E 10.2 0.05 
8 C 24 . 0 8 D 20.0 .. 
8 C 24.0 8 E 10.2 0.05 
8 D 20.0 8 E 10.2 . . 
NOTE: 1 . See opposite page for explanatory code 
of group numbers 
2. The symbol means statistically 
insignificant 
- ·53 -
4 . 1.9 LOW BACKACHE 
The number and incidence of patients affected by low 
backache in the various groups investigated is shown in 
Tables 23 and 24. The effect of oestrogen and placebo 
therapy on low backache in oophorectomized females is 
also shown in Table 24. The statistical comparison for 
significant differences between the groups studied in the 
incidence of backache is summarised in Table 25. 
Despite a few relationships of doubtful significance 
there would seem to be only one interpretation of these 
results, namely that backache is not a factor related to 
oophorectomy and similarly cannot be relieved by oestrogen 
therapy. Moreover, it is considered significant that low 
backache, being more real a symptom than, for example, 






























































































































































































































































































































































































































































































































































































































































































































































EXPLANATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy t i.e. Groups 2+3+4+5) 
Control - variable time< 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 25 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED AND THE OVERALL INCIDENCE OF LOW BACKACHE 



































GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
OVERALL GROUP OVERALL P< 
INCIDENCE OF NO. INCIDENCE OF 
LOW BACKACHE LOW BACKACHE 
33.3 2 14.3 .. 
33.3 3 46.2 . . 
33.3 4 38.9 . . 
33.3 5 10 . 0 . . 
33.3 6 12.5 . . 
33.3 7 44.4 . . 
14 . 3 3 46.2 0.05 
14.3 4 38.9 0.05 
14.3 5 10.0 .. 
14.3 6 12.5 . . 
14.3 7 44 . 4 0.05 
46.2 4 38.9 .. 
46.2 5 10.0 0.05 
46.2 6 12.5 0.05 
46.2 7 44.4 .. 
38.9 5 10.0 0.05 
38.9 6 12.5 0.05 
38.9 7 44.4 . . 
10.0 6 12.5 .. 
10.0 7 44.4 0.05 
12.5 7 44.4 0.05 
32 . 0 8 B 28.0 .. 
32.0 8 C 28.0 . . 
32.0 8 D 30.0 . . 
32.0 8 E 24.5 . . 
28.0 8 C 28.0 • i, 
28.0 8 D 30.0 . . 
28 . 0 8 E 24.5 . . 
28.0 8 D 30.0 . . 
28 . 0 8 E 24.5 .. 
30.0 8 E 24.5 . . 
1. See opposite page for explanatory code 
of group numbers 




The number and incidence of patients complaining of 
severely decreased or absent libido in the various groups 
investigated is shown in Tables 26 and 27. The effect of 
oestrogen and placebo therapy on libido in oophorectomized 
females is also shown in Table 27. The statistical comparison 
for significant differences between the groups studied in 
the incidence of absent libido is summarised in Table 28. 
No females in the normal premenopausal group complained of 
absent libido. On the other hand there was a high incidence of 
this complaint in all the groups of patients having undergone 
surgery. The strikingly high incidence of this symptom in the 
immediate postoperative groups (Groups 2 and 5) is not 
unexpected in view of the proximity to surgery. Nevertheless, 
the groups investigated 6 months and 2 years postoperatively 
(Groups 3, 4, 6 and 7) presented an incidence of absent libi do 
varying from 25.0% to 44.0% and these figures showed a 
statistically highly significant difference (p <:0.001) to the 
' 
normal premenopausal patients. Furthermore, there was no 
effect on this symptom by oestrogen or placebo therapy. 
The interpretation of these results would appear to be 
that the operation of hysterectomy per se, irrespective of 
whether the ovaries are removed or not, is associated with a 
significant reduction of libido. Moreover, oestrogen therapy 
is shown to be of no benefit in the treatment of decreased 




























































































































































































































































































































































































































































































































































































































































































































EXPLANATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediate ly 
post-oophorectomy 
Premenopausa , investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy t i.e. Groups 2+3+4T5) 
Control - variable time< 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 28 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED AND THE OVERALL INCIDENCE OF ABSENT LIBIDO 



































GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
OVERALL GROUP OVERALL P< 
INCIDENCE OF NO. INCIDENCE OF 
POOR LIBIDO POOR LIBIDO 
0 2 71.4 0.001 
0 3 38.5 0.001 
0 4 44.4 0.001 
0 5 80.0 0.001 
0 6 25.0 0.001 
0 7 33.3 0.001 
71.4 3 38.5 0.01 
71.4 4 44.4 0.05 
71.4 5 80.0 . . 
71.4 6 25.0 0.01 
71.4 7 33.3 0.01 
38.5 4 44.4 .. 
38.5 5 80.0 0.01 
38.5 6 25.0 . . 
38.5 7 33.3 .. 
44.4 5 80.0 0.05 
44.4 6 25.0 . . 
44.4 7 33.3 .. 
80.0 6 25.0 0.01 
80.0 7 33.3 0.01 
25.0 7 33.3 . . 
52.0 8 B 48.0 . . 
52.0 8 C 48.0 . . 
52.0 8 D 54.0 . . 
52.0 8 E 55.1 . . 
48.0 8 C 48.0 . . 
48.0 8 D 54.0 . . 
48.0 8 E 55.1 .. 
48.0 8 D 54.0 .. 
48.0 8 E 55.1 .. 
54.0 8 E 55.1 .. 
1. See opposite page for explanatory code 
of group numbers 
2. The symbol •• means statistically 
insignificant 
- 55 -
4 • 1 . 11 OTHER SYMPTOMS 
4.1 . 11.1 VAGINAL BLEEDING 
This symptom was not analysed in this thesis for the reason 
that no. patients were accepted to the study with postmenopausal 
bleeding and all patients receiving oestrogen therapy had 
undergone hysterectomy. Thus, although included on the original 
trial form, the heading in fact was redundant. 
4.1.11.2 PERSPIRATION 
The incidence of perspiration was the same as that of hot 
flushes. The figures are not presented in order to prevent 
repetition . All corrunents with regard to the symptom of hot 
flushes apply similarly to the symptom of perspiration. 
4.1.11.3 MOOD CHANGES 
The assessment of mood change in a large group of patients 
each seen over a period of one year was extremely difficult and 
open to too great a margin of error and personal bias. This 
factor was therefore excluded from the study. 
4.1 . 11.4 PRURITUS VULVAE AND DYSPAREUNIA 
Dyspareunia is considered under Section 4.1.2 Atrophic 
Vaginitis. 
The incidence of pruritus vulvae in all groups of patients 
studied was insignificant and no corrunent on this symptom is 
... possible. 
- 56 -
4 . 1.12 OVERALL IMPRESSION OF RESPONSE TO TREATMENT 
The score on which this assessment is based is defined 
and discussed under Section 3.2.2 . 
The overall clinical impression as to the general response 
of the oophorectomized female to oestrogen and placebo therapy 
is indicated in Table 29, together with the chi square 
distribution for statistical significance. Further statistical 
comparison between the groups on the various forms of treatment 
is tabulated in Table 31. 
The statistical evaluation in this instance requires some 
qualification. The score of assessment was partially 
non-parametric; however the results, as shown below, demonstrate 
striking trends which are of such a degree that, on the advice 
of a statistician, non-parametric tests of significance were 
considered unnecessary. The statistical evaluation is thus 
presented for the sake of completeness. 
The patient's personal impression as to her own overall 
response to treatment, in this instance oestrogen or placebo 
in the form of a single blind cross-over trial, is shown in 
Table 30. This table also indicates the chi square distribution 
for statistical significance. The groups receiving the various 
forms of treatment are further individually compared to each 
other for statistical differences and the results listed in 
Table 32. 
Thus Tables 29 and 31 indicate the investigator's 
impression and Tables 30 and 32 indicate the patient's 
impression, i.e. Table 29 is analagous to Table 30 and Table 31 
to Table 32. Comparison of these two analagous groups of 
tables show the results of the statistical tests in each 
instance to be identical. The presentation of the results 
- 57 -
below takes this fact into account. 
Oestrogen and placebo therapy are both demonstrated to 
have a highly significant 'tonic effect' on the patient and 
this is borne out by both the observer's assessment and the 
patient's impression (p <(0.001). That this is not purely a 
psychological response to an interested physician is shown 
statistically (Tables 31 and 32) and confirmed by the 
following finding of significance : Comparison of the oestrogen-
treated groups (Groups 8B, 8C and 8E) to the groups of the 
same patients after single blind cross-over to placebo 
(Group 8D) indicates that there was a significant deterioration 
in the patient's overall feeling of well-being whilst on 
placebo (p <(0.01) . Nevertheless, a large proportion of 
patients were unaware of the change from oestrogen to placebo 
and comparison of the control and placebo groups indicates 
a statistically highly significant difference (p <(0.001). 
The possible interpretation of these results is 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EXPLANATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
All patients investigated and treated 
post-oophorectomy 
Control - variable time < 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 31 
TREATED GROUPS STATISTICALLY COMPARED FOR OVERALL 
IMPROVEMENT ON THERAPY (OBSERVER'S ASSESSMENT) 
GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
GROUP OVERALL GROUP OVERALL P· < 
NO. INCIDENCE NO. INCIDENCE 
. .. 
8 A 0 8 B 82.0 0.001 
8 A 0 8 C 80.0 0.001 
8 A 0 8 D 42.0 0.001 
8 A 0 8 E 79.6 0.001 
8 B 82.0 8 C 80.0 .. 
8 B 82 . 0 8 D 42.0 0.01 
8 B 82.0 8 E 79.6 . . 
8 C 80.0 8 D 42.0 0.01 
8 C 80.0 8 E 79.6 . . 
8 D 42 . 0 8 E 79.6 0.01 
TABLE 32 
TREATED GROUPS STATISTICALLY COMPARED FOR OVERALL 














GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
OVERALL GROUP OVERALL P< 
INCIDENCE NO. INCIDENCE 
. 
0 8 B 80.0 0.001 
0 8 C 88.0 0.001 
0 8 D 48.0 0.001 
0 8 E 81. 7 0.001 
80.0 8 C 88.0 .. 
80.0 8 D 48.0 0.01 
80.0 8 E 81.7 .. 
88.0 8 D 48.0 0.01 
88.0 8 E 81.7 .. 
48.0 8 E 81.7 0.01 
1. See opposite page for explanatory code 
of group numbers 
2 . The symbol means statistically 
insignificant 
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4.2 ANALYSIS OF SIGNS 
4 . 2 .1 BODY WEIGHT 
The mean body weight of the patients in the various groups 
studied is shown in Table 33 . This table indicates that the 
mean body weight in the several groups varied between 122.63 
and 162.67 . This wide variation is reflected in the standard 
deviations and standard errors and no purpose is served by 
comparing these groups statistically. 
The group of oophorectomized patients undergoing the 
trial scheme o f therapy, however, could be compared statist!cally 
as this was an identical group being compared on different 
forms of therapy. The effect of oestrogen and placebo therapy 
on the body weight of these oophorectomized females is shown 
in Table 34. 
The mean body weight, standard deviation and standard 
error of these groups are remarkably similar and statistically 
show no difference. It may therefore be concluded that the 
administration of oestrogens to oophorectomized females 
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4.2 . 2. DIASTOLIC BLOOD PRESSURE 
The mean diastolic blood pressure of the various 
groups investigated is shown in Table 35. These figures 
are presented for the sake of completeness and to indicate 
that none of the patients admitted to the study was suffering 
from any major degree of hypertension. 
The effect of oestrogen and placebo therapy on the 
diastolic blood pressure of oophorectomized females is 
indi cated i n Table 36. No statistical differences of 
significance were demonstrat ed between any of the groups. 
It is concluded that oestrogen therapy does not cause a 

































































































































































































































































































































































































































































































































































































































































































































































































































4.2 . 3 BREASTS 
The clinical state of the breasts viz. normal or atrophic 
in the several groups of patients investigated is listed in 
Table 37. The effect of oestrogen and placebo therapy on 
this clinical state in oophorectomized females is considered 
in Table 38 . The statistical comparison for significant 
differences between the groups of patients investigated and 
the overall incidence of atrophic breasts is summarised in 
Table 39 . 
There is a stati stically highly significant difference 
in the incidence of atrophi c breasts in all the oophorectomized 
groups of patients as compared with the normal premenopausal 
group of patients (p <:0.001 ). 
Comparison of the oophorectomized and non-oophorectomized 
groups of patients assessed 6 months after surgery indicates 
a significantly higher incidence of atrophic breasts in t he 
oophorectomized group (p <:0.01 ) . This relationship also 
exists for the 2 year groups, but to a lesser degree of 
statistical significance (p <:o.05). 
However, a highly significant difference exists between 
the normal premenopausal group and that group of patients 
investigated two years after hysterectomy with conservation of 
ovaries (p <:o.ool). Thi s is an unexpected finding. 
All patients i n the postmenopausal group (100%) assessed 
immediately after oophorectomy had atrophic breasts and statis-
tical differences were found in comparing this group to the 
normal premenopausal females (p <:0.001 ) ; the premenopausal 
patients assessed immediately post-oophorectomy (p <:o.01); 
the premenopausal patients assessed 6 months after hysterectomy 
with conservation of ovar i es (p <:0.001) and the premenopausal 
- 61 -
patients assessed 2 years after hysterectomy with conservation 
of ovaries (p <:o.Ol). 
Oestrogen therapy produced no alteration in the clinical 
state of the breasts of oophorectomized females. 
The most logical interpretation of the above results 
would seem to be that normal ovarian function is necessary 
for the maintenance of · normal breast configuration. 
Oophorectomy results in atrophy of the breasts. Similarly, 
decreased ovarian function after the menopause has the 
same effect . Despite these findings, exogenous oestrogen therapy, 
of the t wo types used in the present investigation, has been 
shown to be of no value in restoring atrophic breasts to 























































































































































































































































































































































































































































































































































































































































































































































EXPLANATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post.-oophorectomy i.e. Groups 2+3-r4+5) 
Control - variable time< 2 years 
post-oophorectomy 
3 months continuous oestrad1ol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 39 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 




































GROUPS COMPARED STATISTICAL 
SIGNIFICANCE 
OVERALL GROUP OVERALL P< 
INCIDENCE OF NO. INCIDENCE OF 
ATROPHIC ATROPHIC 
BREASTS BREASTS 
11.1 2 50.0 0.001 
11.1 3 61.5 0.001 
11.1 4 72.2 0.001 
11.1 5 100.0 0.001 
11.1 6 25.0 . . 
11.1 7 50.0 0 . 001 
50 . 0 3 61 . 5 .. 
50.0 4 72.2 .. 
50 . 0 5 100.0 0.01 
50.0 6 25.0 0 . 05 
50.0 7 50.0 .. 
61.5 4 72.2 . . 
61.5 5 100.0 0.05 
61.5 6 25 . 0 0.01 
61.5 7 50.0 .. 
72.2 5 100 . 0 0.05 
72.2 6 25.0 0.01 
72.2 7 50.0 0.05 
100.0 6 25.0 0.001 
100.0 7 50.0 0.01 
25.0 7 50.0 0.05 
66.0 8 B 62.0 .. 
66.0 8 C 68.0 .. 
66.0 8 D 74.0 . . 
66.0 8 E 65.3 .. 
62.0 8 C 68.0 . . 
62 . 0 8 D 74 . 0 . . 
62.0 8 E 65.3 .. 
68.0 8 D 74.0 . . 
68.0 8 E 65.3 .. 
74 . 0 8 E 65 . 3 .. 
1. See opposite page for explanatory code 
of group numbers 




4.2.4 . OTHER SIGNS 
4 . 2 . 4.l HAIR TEXTURE 
Hair texture proved to be an extremely difficult 
sign in which to determine change. It is therefore not 
possible to present any meaningful figures. Nevertheless, 
after assessment of the patient's response to history 
(any gain or loss of hair, change in quality, etc.) and 
the author's personal impression, the conclusion arrived 
at is that both oophorectomy and subsequent exogenous 
oestrogen therapy appear t o have little effect on the 
quality or texture of scal p hair. 
4 . 2 . 4 . 2 SKIN THICKNESS 
Skin thickness results are not presented because 
skin-fold measurements subsequently proved to be inaccurate 
in the obese pati ent. Exclusion of these patients from the 
sub-groups investigated reduced the size of the groups 
so that statistical evaluation would have been meaningless. 
It was therefore not possible to arrive at any conclusion 
with regard to skin thickness. 
4.2.4 . 3 HEIGHT 
No change in body height was demonstrated in the 
oophorectomized group of patients receiving oestrogen therapy. 
No purpose is therefore served by presenting these figures 
and they have been excluded from the study. 
- 63 -
4.3 VAGINAL SMEAR 
The details of the vaginal epithelial cell counts of 
all patients investigated in this study appear in Appendix B 
(Tables B . l and B.2) as Maturation Indices (parabasal: 
intermedi ate : superficial cell types). The vaginal epithelial 
cell types, with mean,standard deviation. , standard error 
and statistical significance in the several groups of 
patients investigated, are shown in Table 40. The effect 
of oestrogen. and placebo therapy on the vaginal epithelial 
cell types (meanv standard deviation, standard error and 
statistical significance) of oophorectomized females is 
summarised in Table 41. These changes are diagrammatically 
represented in Figure 2. 
The mean maturation indices of the normal premenopausal, 
6 month-post-hysterectomy-conserved-ovaries and 2 year post-
hysterectomy-conserved-ovaries groups were 1°22 8 9 • 00 : 9 • 7 8 , 
a .co: 92 °87 : 7°13 and 2°44 91-33 : 6°23 respectively. 
These all i ndicate an absent or low parabasal cell count 
with the majority of cells being of intermediate type. The 
superficial cell counts are relatively low. 
The mean parabasal cell counts in the oophorectomized 
groups range from 4°69 to 15 °22; mean intermediate- cell counts . . ,,, •... 
j •..f•,r 
from 79 . 93 to 84 °23 and mean superficial cell counts from 
3 . 33 to 11 °08. 
The statistical comparison between the groups with intact 
ovar i es against those without ovaries indicates a highly 
s i gni ficant difference for the parabasal cell counts (p <(0.005), 
but not for the i ntermediate or superficial cell counts. 
Oestrogen therapy is shown to promote the maturation 
of vaginal epithel i al cells from the parabasal to the 
- 64 -
intermediate type (Table 41 and Figure 2 ) . Numerically, 
however, the only cell type to reflect a significant change 
i s the parabasal . The mean parabasal control value of 
11 - 54 is reduced to 0 . 54 after 3 months' continuous oestradiol 
valerate therapy and is 1 - 12 at 6 months. Single blind 
cross-over to placebo results in a significant rise of the 
mean value to 8°34. The final cross-over of placebo to 
conjugated oestrogen results in a drop of the mean value, 
once again, to 0°71 . These results are statistically highly 
significant (p <:0 . 0005). Th e mean intermediate cell count 
ranged between a control value of 81°70 and 93·29 after 3 
months' conjugated oestrogen therapy. This difference is not 
statistically significant. 
The superficial cell count varied between mean values 
of 2°16 and 8 °04 (Table 41), the former following placebo 
therapy and the latter after 6 months' continuous oestradiol 
valerate therapy. The fact that continuous high dosage 
oestrogen therapy was unable to raise the superficial cell 
index beyond a mean of 8°04 is considered to be a significant 
finding. 
There was no statistical difference between the two types 
of oestrogen used in their effect on the vaginal epithelium. 
In summary, therefore, the above results demonstrate that 
oophorectomy produces a statistically significant increase in 
the vaginal smear parabasal cell count and this response is 
reversed by the administration of exogenous oestrogens 
p <:0 . 0005 ) . No significant changes in the intermediate or 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































DIAG'R,A11MATIC REPRESENTATION OF CHANGE IN MATURATION 
INDEX INDUCED BY OESTROGEN AND PLACEBO THERAPY. 
VISIT 
3 = 6 
1 = CONTROL; 2 = 3 MONTHS OESTRADIOL VALERATE; 
MONTHS OESTRADIOL VALERATE; 4 = PLACEBO; 
5 = 3 MONTHS CONJUGATED OESTROGEN THERAPY. 
1 
-. . . . . . . . . . •• . .. . . . . . . . . . . • • ... . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . .. . . . • • ... . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . • • ... . . . . . . . . . . • • ... • • ... . . . . . . . . . . • • ... • • ... . . . . . . . . . . • • ... . . . . . . . . . . . . . . . . . . . . . . . . . • • ... . . . . . . . . . ~ 
2 
-. . . . . . . . • • ... . . . . . . . . . . . . ... . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . .. . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . • • • ... . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . • • ... . . • • • ... . . . . . . . . . . . . • • ... . . . . . • • ... . . 
3 
-• •• . .. .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . .. . . ... • • ... . . . .. • • ... . . . .. . . . .. . . . .. . . . .. . . . .. . . . . . • • ... . . . .. . . . .. . . . . . . . . . . • • ... . . . .. . . . .. . . . .. • • ... . . . . . • • ... • • ... . . . .. • • ... . . . .. .. . .. . . . .. . . . .. . . • •• . .. .. .. • •• . .• •• . .• •• . .. .. • • ... •• 
4 
-.-.. • •• . .• • • • • • • • • • ... • • • • • ..
····· . . . • • ••••• . . . . . . . . . . . . . . . . . . . . . . . . . • • • ..
••••• 
····· • • • ... . . . . 
····· . . . • • ... . . . .. . . . . . • • ... • • ... • • ... • • ... • • • •• • • ... . . • •• . .• •• • • ... . . • •• . .
····· . .. . .• •• . .• •• . .
••••• . .. • • ... 
••••• 
·=·=· . .. • • ... 
5 
.. ... . . . .. . . . .. . . . .. . . . .. .. . .. . . . .. . . . .. . . . .. • • ... . . . .. . . . .. . . . .. . . . .. . . . .. . . . .. • • ... • • ... • • ... • • ... • • ... . . . .. . . . .. • • ... . . . .. . . . .. . . . .. . . . .. . . . .. • • ... • • ... • • ... . . • •• . .• •• . .. .. • • ... . . • •• • • • •• . .• •• • • ... • • ... • • ... •• . .. •• . .. • • • •• • • ... 
MEAN 11·5/81·7/6·8 
No of Cases so 50 so 50 49 
Vaginal Cells,_ Parabasal • · Intermediate;-;.; Superficial D 
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4. 4 SERUM CHOLESTEROL 
The serum cholesterol values of all patients investigated 
in this study appear in Appendix C (Tables C.l and C.2). 
The mean values in mg per 100 ml, with standard deviation 
and standard error, of the several groups investigated appear 
in Table 42 and the response to oestrogen and placebo therapy 
is indicated in Table 43. The statistical comparison between 
these groups for significant differences in serum cholesterol 
values appears in Table 44. 
The mean serum cholesterol of the several groups 
investigated ranged from 241.60 to 268.56 (S . D.:30.23 to 54.82; 
S. E. : 4 • 3 2 to 2 0 • 9 5) • 
There is considerable overlap in these values and no 
significant statistical differences exist between the various 
groups investigated (Table 44). For example, oophorectomy is 
not shown to increase significantly the serum cholesterol value. 
Thus no differences are found by comparing the 6 month oophorec-
tomized group mean value of 250-85 with the 6 month conserved-
ovary group mean value of 242°00; nor by comparing the mean 
values of 265-44 and 260°39 of the 2 year groups without and 
with ovaries respectively. 
Oestradiol valerate therapy to oophorectomized females 
reduced the mean control value from 255°08 mg per 100 ml to 
244.44 at 3 months and 242°04 at 6 months. Cross-over to 
placebo resulted in an increase to 259°72 mg per 100 ml. This 
effect of oestradiol valerate on the reduction of serum 
cholesterol value was of possible significance (p <(0.05). 
Conjugated oestrogen therapy, however, had no significant effect. 
Thus, the present investigation has not shown oophorectomy 
to result in a significant increase in the serum cholesterol 
- 66 -
value . Nevertheless, oestrogen therapy in the form of 
oestradiol valerate was of benefit in reducing the 


























































































































































































































































































































































































































































































































































































































































































































































































EXPLANATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated irmnediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy t i.e. Groups 2+3+4+5) 
Control - variable time < 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 44 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED FOR SIGNIFICANT DIFFERENCES IN BLOOD 
CHOLESTEROL VALUES 
GROUPS COMPARED STATISTICAL SIGNIFICANCE 






















TO GROUP NO . DEGREES T VALUE p =< 
FREEDOM 
~ 
2 21 0.8311 . . 
3 20 1.1040 .. ... 
4 25 0.1804 . . 
5 12 1.4495 . . 
6 15 1. 4394 . . 
7 25 0.4749 . . 
3 25 0.0197 . . 
4 30 0.8 780 .. 
5 17 0.9937 . . 
6 19 0.6302 . . 
7 34 0.6670 . . 
7 24 1 .5554 .. 
8 B 98 1.3112 .. 
8 C 98 1.6626 0.05 
8 D 98 0.5031 . . 
8 E 97 0.1328 . . 
8 D 98 1. 7615 0.05 
8 E 97 1.1899 .. 
8 D 98 2.0996 0 . 025 
8 E 97 0.6332 .. 
1. See opposite page for explanatory code 
of group numbers 

























4 , 5 CALCIUM,PHOSPHO~US AND ALKALINE PHOSPHATASE 
Plasma calcium, inorganic phosphorus and alkaline 
phosphatase values of all patients investigated in this study 
appear in Appendix D (Tables D. l, D.2, D. 3 and D. 4 ). Mean 
plasma calcium (in mg per 100 ml) inorganic phosphorus 
(in mg per 100 ml) and alkaline phosphatase values f i n 
Bodansky-Reinhart units ) of the groups of patients studied 
appear in Table 45. The response of plasma calcium, inorganic 
phosphorus and alkaline phosphatase values (all with mean, 
Standard Deviation - S.D . and Standard Error - S . E.) of 
oophorectomized patients following oestrogen and placebo 
therapy is summarised in Table 46. The statistical comparisons 
between the groups of patients investigated,for significant 
differences in plasma calcium and inorganic phosphorus, appear 
in Tables 47 and 48 respectively . 
There was a range for plasma calcium in the groups s tudied 
of 9°48 to 9°88 mg per 100 ml (Table 45). The statistical 
comparison between these groups showed no significant differences 
(Table 47). Hence comparison between normal premenopausal 
patients and groups following hysterectomy with and without 
ovarian conservation showed no difference in the range of 
values of plasma calcium. Nevertheless, administration of 
conjugated equine oestrogen resulted in a significant lowering 
of the mean plasma calcium value to 9 . 24 from a control value 
of ·9 · 68 p <:o . 0025) and a placebo value of 9.55 (p <:o.Ol). 
In this effect conjugated oestrogen was also shown to be 
statistically superior to oestradiol valerate .(p ~0. 0125). 
The plasma inorganic phosphorus results were more difficult 
to interpret (Tables 45 and 48). The mean range for plasma 
inorganic phosphorus values i n the grol.Ws studied was 2°99 
- 68 -
to 3 • 93 . Excluding the 2 year-post-hysterectomy-conserved-
ovaries group (Group 7 ) , this range was 3 • 46 to 3 • 93. The 
mean value of 2 • 99 in Group 7 was thus strikingly low and 
showed statistical differences to the normal premenopausal 
(p <0 . 005) 2 year-post-oophorectomy (p <0 . 0005 and 
6 month-retained-ovaries (p <0 . 005 ) groups. The mean normal 
premenopausal value was 3·61. The immediate post-oophorectomy 
value of 3·93 was higher but not significantly different, 
although this value fell to 3·53 at 6 months post-oophorectomy 
(p <:0 . 05 ) and to 3 · 46 at 2 years (p <:0 . 01 . Neither of these 
latter two values differed significantly from the normal 
premenopausal value. Comparison of the mean values of 3·53 
and 3 · 57 for the 6 month oophorectomized and conserved-ovaries 
groups respectively showed no statistical s i gnificance. 
Although these findings suggest that the ovary is effective 
in either producing a reduction in or preventi ng an elevation of 
plasma inorgani c phosphorus, it is nevertheless i mpossible to 
place any strict interpretation on these results. 
The effect of exogenous oestrogen replacement therapy on 
plasma inorganic phosphorus values in the oophorectomized 
female is thus considered to be of importance . In fact, such 
therapy is shown to be effective in reducing the level of 
plasma inorganic phosphorus (Tables 46 and 48 ) . Both forms 
of oestrogen used in this study were equally effective. 
Oestradiol valerate therapy for 3 months resulted in a reduction 
, of the mean value from 3 °63 to 3.39 (p ,<0 . 025). Assessment 
after 6 months of oestradiol valerate showed a mean value of 
3 . 49 and this was not significantly different from the original 
mean control value . Re-conversion to placebo resulted in an 
increase of the mean value to 3 °62, a value similar to that 
of the original control group. The subsequent cross-over to 
- 69 -
conjugated oestrogen resulted in a statistically highly 
significant drop of the mean values from 3.62 to 3.24 
/ 
(p <:0.0025) and comparison of this latter value with the 
original mean control value was also statistically highly 
significant (p <0.0005). 
The average values for alkaline phosphatase in all the 
groups investigated were well within the range of normality 
(2.52 to 4.58 Bodansky-Reinhart Units). This is supportive 
evidence that no patients admitted to the investigation were 
suffering from any manifest form of bone disease. The mean 
values with S.D. and S.E. are presented for the sake of 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EXPLANATION OF GROUP NUMBERS DESCRIBED 
IN TABLE OF STATISTICAL COMPARISON 
DESCRIPTION OF GROUP OF PATIENTS 
Normal premenopausal 
Premenopausal, investigated immediately 
post-oophorectomy 
Premenopausal, investigated 6 months 
post-oophorectomy 
Premenopausal, investigated 2 years 
post-oophorectomy 
Postmenopausal, investigated immediately 
post-oophorectomy 
6 months post-hysterectomy with conserved 
ovaries 
2 years post-hysterectomy with conserved 
ovaries 
All patients investigated and treated 
post-oophorectomy (i.e. Groups 2+3+4T5} 
Control - variable time< 2 years 
post-oophorectomy 
3 months continuous oestradiol valerate 
therapy 
6 months continuous oestradiol valerate 
therapy 
3 months continuous placebo therapy 
3 months continuous conjugated oestrogen 
therapy 
TABLE 47 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED FOR SIGNIFICANT DIFFERENCES IN PLASMA 
CALCIUM VALUES 
GROUPS COMPARED STATISTICAL SIGNIFICANCE 





















TO GROUP NO. DEGREES T VALUE p =< 
FREEDOM 
2 21 0.0975 .. 
3 20 0.4939 . . 
4 25 0 . 5362 .. 
5 12 0. 742 3 . . 
6 15 o.4595 .. 
7 25 0.054 7 .. 
3 25 0.5568 .. 
4 30 0.7773 . . 
6 19 0.8092 .. 
7 34 1. 3181 .. 
7 24 0.4723 .. 
8 B 98 1.0759 .. 
8 C 98 0.6589 .. 
8 D 98 1.1000 .. 
8 E 97 3.2093 0.0025 
8 D 98 0.0304 .. 
8 E 97 2 . 2822 0.0125 
8 D 98 0.4054 .. 
8 E 97 2.4343 0.01 
1. See opposite page for explanatory code 
of group numbers 





















0 . 02 
TABLE 48 
STATISTICAL COMPARISON BETWEEN THE GROUPS OF PATIENTS 
INVESTIGATED FOR SIGNIFICANT DIFFERENCES IN PLASMA 
INORGANIC PHOSPHORUS VALUES 























TO GROUP NO. DEGREES T VALUE p =< 2P 
FREEDOM 
2 21 1. 4166 .. 
3 20 0.3729 .. 
4 25 0.8016 . . 
5 12 0.1099 .. 
6 15 0.1084 .. 
7 25 3.0441 0.005 
3 25 1. 9664 0.05 
4 30 2.6756 0.01 
4 29 0.8203 . . 
6 19 0.1501 .. 
7 34 4.0894 0.0005 
7 24 2.9881 0.005 
8 B 98 2 .080 0.025 
8 C 98 1.1714 . . 
8 D 98 0.087 .. 
8 E 97 3.4638 0.0005 
8 D 98 1.8205 0.05 
8 E 97 1.2086 .. 
8 D 98 0.9990 .. 
8 E 97 3.0658 0.0025 
1. See previous page for explanatory code 
of group numbers 
























4 . 6 COMPLICATIONS OF THERAPY 
4.6.1 NAUSEA AND VOMITING 
The incidence of nausea and vomiting shown i n Table 49 
was statistically significant after 3 months of oestrogen 
therapy, irrespective of the type used (p < 0 . 0 1 , the 
respective incidences being 12% with oestradiol valerate 
and 18·4% with conjugated equine oestrogens . The incidence 
decreased to 4% after 6 months of oestradiol valerate therapy, 
a figure similar to that of the placebo group . 
Nausea is thus demonstrated to be a side effect of 
oestrogen therapy although the high incidence found is most 
probably related to the high dosage of hormone administered 
during this trial. 
4.6.2 FACIAL HAIR 
Seventeen (34 per cent of the 50 oophorectomized 
patients exhibited some degree of facial hirsuties as determined 
both by clinical examination and photographic evidence (face 
and profile) at the first (control) visit. No further patient~ 
developed hirsuties during the programme of investigation. 
4.6.3 ALLERGIC MANIFESTATIONS 
No allergic manifestations to the hormones administered 
occurred during the investigation. 
4.6.4 ACNE 
No cases of acne resulted from either of the types of 











THE INCIDENCE OF NAUSEA AND VOMITING IN OOPHORECTOMIZED 
FEMALES ON OESTROGEN AND PLACEBO THERAPY 
3 MONTHS 6 MONTHS 3 MONTHS 3 MONTHS 
CONTROL OESTRADIOL OESTRADIOL PLACEBO CONJUGATED 
VALERATE VALERATE OESTROGENS 
No. % No. % No. % No. % No. % 
50 100 50 100 50 100 50 100 49 100 
. 
50 100 44 88.0 48 96.0 48 96.0 40 81.6 
0 0 6 12.0 2 4 . 0 2 4.0 9 18.4 
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4 . 6 "5 VASCULAR THROMBOSIS 
One patient presented with superficial thrombophlebitis 
of a varicose vein 4 weeks after commencing conjugated 
equine oestrogen therapy. This responded completely to 
supportive therapy and the oestrogen therapy was not 
discontinued at any stage. It is not possible to c onunent 
on whether this case was a complication of oestrogen therapy 
or a purely coincidental event. 
No cases of deep vein thrombosis, pulmonary embolus, 
myocar dial infarction or cerebral infarction occurred 




5 . DISCUSSION 
5 ¢ 1 CLINICAL FEATURES' ·oF· 'POSTMENOPAUSE, OOPHORECTOMY AND 
OESTROGEN THERAPY 
The lack of general agreement as to the precise 
symptomatology of the climacteric is reviewed in Part 1.3 . 
It is stressed that there is no scientific evidence 
differentiating those symptoms related to oestrogen 
withdrawal from the broad group of symptoms which may be 
due to the concurrent ageing process or general environmental 
problems . 
The results of the present investigation would thus 
appear to be of value in that a wide spectrum of symptomatology 
has been analysed and those symptoms related directly to 
oestrogen wi thdrawal following bilateral oophorectomy have 
been defined. Moreover, further evidence of oestrogen 
dependence is presented by differentiating those symptoms 
responding to exogenous oestrogen replacement therapy from 
those symptoms responding to placebo therapy .• 
The symptoms, sone of which are discussed individually 
below , are shown to fall into 5 (five) possible groups 
l o Symptoms directly related to oophorectomy and significantly 
relieved by exogenous oestrogen therapy· 
A . Hot flushes and perspiration 
B. Atrophic vaginitis (pairt, dyspareunia or 
blood-stained discharge) 
2 . Symptoms directly related to oophorectomy but not 
relieved by exogenous oestrogen therapy 
A. Angina pectoris 
B. Depression 
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3. Symptoms not related to oophorectomy and possibly 
relieved by exogenous oestrogen therapy 
A. Headache 
B. Irritability 
4. Symptoms significantly relieved by placebo therapy 





5. Symptoms not related to oophorectomy nor relieved by 
either exogenous oestrogen or placebo therapy 
A. Low backache 
B. Decreased or absent libido (Fri gidity ) 
Consideration of the results presented (Part 4 ) and the 
above grouping of symptomatology leads to the conclusion that 
the only true symptoms of the climacteric relate to hot flushes 
and atrophic vaginitis. The only other symptom that could 
remotely be included in this group is that of headache. In 
this instance, however, there was- no relationship to 
oophorectomy and the response to conjugated oestrogen therapy 
was of insufficient significance to so relate this symptom. 
There was a significant incidence of angina pectoris (p <(0.01) 
and depression· (p<:0.05) following oophorectomy but both 
responded significantly to placebo therapy. These symptoms 
are thus more likely to be psychological responses to the 
operation of oophorectomy than a result of endogenous oestrogen 
withdrawal. For the same reason irritability, which does not 
significantly follow oophorectomy but which is relieved by 
both oestrogen and placebo therapy, is considered not to be 
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a true symptom of the climacteric. This symptom, however, 
will be discussed more fully below. 
The conclusion that the only symptoms directly resulting 
from ovarian oestrogen withdrawal following oophorectomy and, 
by analogy, the normal climacteric, relate to hot flushes 
and atrophic vaginitis, confirms the general impression that 
exists in the medical literature to date (Forman, 1968; 
Greenblatt, 1963; McCandless, 1964; Newton and Odom, 1964; 
Rogers, 1956a; Squires and Cannell, 1952; Tayl or and Rizkal.lah, 
1967; Young, 1939) . 
Despite the above general conclusions, further d i scussion 
on the results relating to certain of the individual symptoms 
is necessary. 
The low incidence of hot flushes in the group of patients 
assessed two years after hysterectomy with conservation of 
ovaries is considered to be a significant finding and an 
important contribution to the present study see Part 4 . 1 . 1 ) . 
This finding, taken into account with factors discussed above, 
is considered sufficient evidence to prove that ovaries 
conserved at the time of hysterectomy on premenopausal women 
are functional and able to prevent oestrogen dependent 
symptoms for at least 2 years after such surgery. Support is 
lent to this argument by the findings of Beavis et al (1969) 
in a study published following the completion of the present 
investigation . The function of ovaries conserved at surgery 
was monitored for periods of 4 to 6 weeks at intervals for 
up to 2~ years by weekly urinary oestrogen and pregnanediol 
measurements . Ovaries which were functioning normally before 
hysterectomy were found to function completely normally after 
hysterectomy . These findings add considerable weight to the 
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arguments that wherever -possible ovar i es should be total l y 
conserved during such surgery. 
Irritability has not been demonstrated to be an effect of 
oophorectomy and is relieved essentially by placebo therapy 
(p <:o.05) (See Part 4.1.7). Conjugated equine oestrogens 
appear to produce some relief of this symptom over and above 
the placebo response (p <:o.05) . Oestradiol valerate was 
ineffective in this respect. Very similar results have been 
shown for the symptom of headache . Dapunt 1967 and Velikay 
(1968) have claimed relief of irritabili ty and headache by the 
use of oestradiol valerate; neither author, however, has 
substantiated his findings with statistical or comparativ e 
evidence . The only conclusion in the light of these findings 
is that irritability and headache are not oestrogen related 
symptoms; the possible relief following oestrogen therapy is 
most likely related to the general feeling of well-bei ng p ~oduced 
by oestrogen, which i s discussed below . 
Angina pect.oris, depression, irritability, palpitati ons 
and insomnia are all symptoms which have been shown to respond 
significantly to placebo (general supportive therapy. Angina 
pectoris, depressi.on and irritability are discussed above . 
The response of palpitati ons to placebo therapy _and the similar 
incidence of this symptom in all groups prior to therapy indicates 
palpitations to be unrelated to oophorectomy and explains the 
lack of response to oestrogen therapy (see Part 4.1 . 4) . 
Insomnia demonstrates an even more striking response t o p ,lacebo 
therapy which weighs agai nst the possible relationship with 
oophorectomy (p < O o 05 ) bei.ng, in this instance, of any 
significance ~ 
Whether the response of these symptoms to placebo warrants 
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such therapy as a routine clinical procedure is conjectural. 
Kupperman et al 1959) state that 'plac ebo therapy i n such 
pa~ients is not a. d1sli_on es t p rocedure but a mea.ns of treating 
a patient ac c ord i ng to t he d ictums of our profession' . 
The symptom of low backache is more real and disabling than, 
say, irritability or insomnia . No significant relationships 
were proven between this symptom and oophorectomy or subsequent 
oestrogen replacement therapy (see Part 4 .1. 9). The relationship 
between low backache, osteoporosis and calcium/phosphorus 
metabolism has been previously reviewed (see Part 1. 4. 3) . 
The inability of oestrogen therapy to relieve low backache 
was considered disappoint i ng, especi ally since oestrogen therapy 
is shown to affect significantly calcium and phosphorus 
metabolism in the present study (see Results, Part 4.5 and 
Discussion, Part 5,4.) These findings are contrary to the 
experience of Wallach and Henneman (1959 ) , who showed oestrogens 
to be of considerable value in the treatment of backache. 
The most significant fi.nding i n relation to the symptom 
of decreased or absent libido (frigidity ) was the high incidence 
of this problem in all the groups of patients havi ng undergone 
surgery, irrespective of whether the ovaries had been conserved 
or not (see Part 4 . 1.10). The high incidence of this symptom 
was not unexpected in the groups assessed shortly after surgery; 
it was not expected in all groups of patients assessed at 
periods of up to 2 years after hysterectomy. The interpretation 
placed on these findings i s that ·the operation of hysterectomy, 
irrespective of whether the ovaries are removed or not, is 
associated with a deleterious effect on libido. Moreover, 
this effect has not been shown to be related to oestrogen 
deprivation; conservation of ovari es does not protect against 
this symptom, nor has replacement oestrogen therapy been shown 
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to be of any value in its treatment. Dapunt (1967) failed to 
show any beneficial effect of oestradiol valerate on libido. 
Oophorectomy was not demonstrated to result i n any obvious 
change in facial features, hirsuties, wrinkling of skin or 
scalp-hair-line configuration. This statement is based on 
evidence obtained by comparing photographs of patients at each 
visit (see Part 3.2.2.) These photographs were remarkably similar 
for any one patient; unfortunately it was not considered practical 
to incorporate into the body of this thesis copies of the 
hundreds of photographs taken during the course of this study. 
Nor, by the same evidence, did exogenous oestrogen therapy 
demonstrate any beneficial effect on the appearance of 
oophorectomized females to whom these hormones were administered. 
It must be conceded that as the time of i nvestigation after 
oophorectomy and the duration of therapy were both short a 
more long-term trial is necessary. Nevertheless, the short 
term effects are considered disappointing . 
The one physical characteristic demonstrati ng significant 
relationship to menopause and oophorectomy was that of breast 
configuration . Menopause and oophorectomy are shown to be 
associated with a .significant degree of breas t atrophy (p < 0.001 
(see Part 4.2 . 3). The finding of a high incidence of atrophic 
breasts in the group assessed 2 years after ovarian conservation 
compared to the normal premenopausal group (p <:o.001) is 
difficult to explain. Furthermore, exogenous oestrogen therapy 
is shown to be of no value in restoring atrophic breasts to a 
nor~al premenopausal state. These factors suggest that 
oestrogens, both endogenous and exogenous, are not the only 
substances necessary for the maintainance of normal breast 
tissue. The present thesis does not allow for conjecture as 
to what these may be. 
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Administration of oestrogens to oophorectomized females 
was shown to produce no significant change in the body 
weight (Part 4.2.1). Nor did such therapy appear to cause 
a change in the diastolic blood pressure (Part 4.2.2). 
This is in cqntrast to the findings of Borgstrom (1954), who 
reported that in 52 cases of hypertension a lowered blood pressure 
followed the administration of oestrogen. Taylor et al (1947), 
however, in a study of 179 oophorectomized women and 21 women 
with natural menopause found no increase in the prevalence of 
hypertension over that occurring in the general population 
and it has been generally agreed that hypertension at the 
menopause is not hormonally mediated. 
The present thesis furnishes statistical confirmation of 
the general tonic effect with exogenous oestrogen therapy 
suggested to exist by several authors (Davis, 1967; Greenhi ll, 
1967; Wilson .and Wilson, 1963). The application of and rationale 
behind a score directed at measuring both the observer's and 
the patient's impression of overall response to therapy is 
outlined in Part 3.2.2. The results and statistical evaluation 
of this scoring system are presented in Part 4.1.12. In summary, 
oestrogen and placebo therapy are both demonstrated to have a 
significant effect in improving the patient's overall feeling 
of well-being and this is borne out by both the observer's 
assessment and the patient's impression (p <:0.001). However, 
single blind cross-over from oestrogen to placebo resulted in 
a significant deterioration in the patient's overall feeling of 
well-being (p <:o.Ol). In this respect both forms of oestrogen 
used in this trial were effective (p <:0.01) . The interpretation 
of these results would suggest that oophorectomized females 
belong to one of three groups. The first group is oestrogen 
deficient and hence responds to oestrogen replacement therapy, 
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irrespective of the type used in the present study. The second 
group responds to oestrogen or placebo therapy hence any 
beneficial effect is most likely psychological in origin and 
not in fact drug related at all. The third group is differentiated 
by its resistance to therapy; both oestrogen and placebo. The 
most likely explanation in this instance is that a general feeling 
of poor health is so firmly entrenched psychologically that it 
cannot be relieved by single placebo therapy. Fortunately this 
latter group was small, less than 20% of patients showing no 
beneficial response at all to therapy. The possible explanation 
for this tonic effect has been theorised by Kupperman et al 
(1959). Kantor et al (1968) have presented a preliminary report 
of an investigation still in progress suggesting that oestrogen 
therapy to ageing women tends to prevent deterioration in 
psychological behaviour. 
The only significant complication or side-effect of oestrogen 
therapy demonstrated in this study was a high incidence of nausea 
and vomiting (see Part 4.6.1). This effect was common to both 
forms of oestrogen administered and is considered to be related 
to the high dosage of hormone used for the purposes of this 
trial. One patient developed a superficial thrombophlebitis 
of a varicose vein 4 weeks after commencing conjugated equine 
oestrogen therapy (see Part 4.6.5). The literature relating 
oestrogens with vascular thrombosis is discussed in Part 1.6 
(Daniel et al, 1967; Jeffcoate et al, 1968; Mozes et al, 1965; 
Poller and Thomson, 1966; Poller et al, 1969; Swyer, 1966; 
Vessey and Doll, 1968, 1969). Although this patient may, in 
fact, represent such a complication, conclusions about the 
frequency of such complications can only be derived from large 
series of patients. Nevertheless, the possibility of oestrogen 
therapy causing thrombosis appears to b~ real and the clarification 
of this problem is considered to be a matter or urgency. 
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5.2 VAGINAL SMEAR 
The literature on vagi.nal smear has been reviewed in Part 
1.4.4. It has been shown that the vaginal smear is a bioassay. 
A positive correlation has been proven between karyopyknotic 
index (KI) and urinary output of oestrone, oestradiol, oestriol 
and total oestrogens in healthy postmenopausal patients 
(Granroos, 1965; Procop,, 1968). 
The overall results of vaginal smear Maturation Indices 
in the present investigation are shown in Part 4.3. The mean 
range of vaginal cel l s represented as percentiles i n the Maturation 
Index in all groups of females i nvestigated prior to any oestrogen 
therapy was as follows : 
Parabasal cells 
Intermediate cells 
Superficial ce l ls 
O - 15.2% 
79.9 - 92 . 9% 
3.3 - 11.1% 
The mean parabasal cells in the groups wi th intact ovaries 
were Oto 2.4%; the range for parabasal cells of the oophorec-
tomized groups was 4 . 7 to 15.2%. The stati stical comparison 
between the oophorectomized and non-oophorectomized groups 
proved the differences to be highly significant (p <: 0.0005). 
These findings are in accordance with those of Granroos (1965), 
Masukawa (1960) and Procope1 (1968 ) . Thus oophorectomy and the 
climacteric, representing a phase of oestrogen deficiency, has 
been clearly proven to be associated with a significant 
percentage of parabasal cells on vagina l smear. Masukawa (1960) 
has observed a gradual increase of parabasal cells with age and 
postmenopausal years . 
The mean range of intermediate cells was 89 . 0 to 92.9% in 
the groups with intact ovaries and 79 . 9 to 84.2% in the castrated 
groups. Although this reflects the change in parabasal cells 
the statistical comparisons between these major groups showed 
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no differences of significance. The total proportion of inter-
mediate cells in postmenopausal women ~as studied by Masukawa 
(1960), who obtained values of 73%, and Gr~nroos (1965), who 
reported values up to 70%. These reports, as with the present 
investigation, indicate intermediate cells to be predominant 
in all groups and both authors were unable to establish any 
distinct correlation with age and postmenopausal years. 
The mean range of superficial cells was 6.2 to 9.8i in the 
groups with intact ovaries and 3.3 to 11.1% for the oophorectomized 
groups. These correspond roughly to the 10% arrived at by 
Masukawa (1960) and the 6% reported by Gr~nroos (1965). Thus 
the share of superficial c~lls is small and the range wide and 
no distinct correlation between the various groups could be 
established. Masukawa (1960) has shown a gradual decrease of 
superficial cells with age and postmenopausal years. 
The Maturation Index (Frost, 1958) has been proposed by 
several authors in the recent medical literature as the sole 
indication for oestrogen treatment of postmenopausal women, a 
high percentage of superficial cells being held as a desirable 
'norm' (Bedford, 1967; Wilson et al, 1963). For example, Bedford 
(1967) has reported superficial cell counts of approximately 
70% for pre-climacteric females and Wilson et al (1963) have 
claimed that with oestrogen therapy they are able to maintain 
superficial cells at 80 - 85% in women aged 45 - 54. Neither 
author presents statistical or comparative data. 
The findings of the present investigation are in conflict 
with those of Bedford (1967) and Wilson et al (1963). Thus, 
although oestrogen therapy to oophorectomized females was shqwn 
to promote the maturation of vaginal epithelial cells from the 
b 1 · I d' d · 1 para asa to interme iate an possib y superficial types, the 
only cell type to reflect a numerical change of statistical 
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significance was the parabasal. The mean parabasal control 
value was reduced from 11.54 to 0.54 after 3 months of oestradiol 
valerate therapy and similar significant differences were 
reflected in the subsequent changes to placebo therapy and again 
to the alternate form of therap¥. 
The intermediate cells reflected these changes but the 
statistical comparisons between the groups showed no correlations, 
positive or negative, of significance. 
The lack of significant response by the superficial cell to 
oestrogen therapy, in view of reports such as those cited above, 
was unexpected and disappointing . The fact that 6 mon~hs' 
continuous oestradiol valerate therapy was unable to raise the 
superficial cells beyond 8.04% is considered to be a finding of 
signific~nce. That this was not a property of the oestrogen 
administered is confirmed by the fact that 3 months' continuous 
high dosage conjugated oestrogen therapy resulted in~ mean 
superficial cell value of no higher than 6.0%. 
The conclusions of the present study, therefore, are that 
oophorectomy produces a statistically highly significant increase 
in the parabasal cell count (p <0.0005), that this response is 
reversed by the administration of exogenous oestrogens, 
irrespective ·of the type used (p <:0.0005) and that the inter-
mediate and superficial cells are of relatively little value in 
estimating the oestrogenic status of the menopausal female. 
For these reasons, control of oestrogen .administ+ation to 
\ 
the postmenopausal or oophorectomized female cannot be determined 
by alteration in the Maturation Index. The most reliable 
cytologic index is the parabasal cell. 
It is therefore suggested that where oestrogen thera~y is 
clinically indicated in postmenopausal patients the parabasal 
cell count expressed as a percentage of all cells present on 
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the vaginal smear should be used as the index of degree of 
response to therapy. The adoption of this suggestion would 
be of considerable value to the cytotechnician. As the 
intermediate and superficial cells may be grouped together 
when counting cells, a considerable amount of time could be 
saved in the evaluation of smears. 
5.3 CHOLESTEROL METABOLISM 
The current medical literature with regard to the 
effects of oestrogen and oophorectomy on the serum 
cholesterol level and the relationship of such levels to 
the development of atheromatosis and coronary artery 
thrombosis is reviewed in Part 1 . 4.2~ The results and 
statistical evaluations of the serum cholesterol investigations 
of the present study are indicated in Part 4.4. 
The results of the present investigation do not show 
any short-term (less than 2 years) effect of oophorectomy on 
the serum cholesterol. Oliver and Boyd (1959) reported _a 
significant elevation of cholesterol in females who had 
undergone bilateral oophorectomy 15 to 20 years previously 
and a similar effect was shown for women who had undergone a 
spontaneous premature menopause (Sznajderman and Oliver, 
1963) . 
Despite the limitations of direct comparison, the 
following summary is of interest: 
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1. Bilateral oophorectomy 37-56 years 251 - 43 mg/100 
15-20 years previously 
(Oliver and Boyd, 1959) 
2. Spontaneous premature 45-49 II 299 II 
menopause 6-20 years 
previously 
Healthy women 45-49 II 217 II 
(Sznajderman and Oliver 
1963) 
3. Normal women 45-65 II 252 II 
(Barr, 1953) 
4. Present study + Normal premenopausal 45-55 II 268 43 II 
Premenopausal immediately + post-oophorectomy 45-55 II 250 54 II 
2 years post-oophorectomy 45-55 II 265 + 41 II 
2 years post-hysterectomy + with conserved ovaries 45-55 II 260 41 II 
Thus the oophorectomized groups of Oliver and Boyd (1959) 
and the present investigation and the normal women of Barr's 
(1953) and the present investigation demonstrate remarkably 
similar results. 
ml 
It is therefore concluded that bilateral oophorectomy in 
the premenopausal female does not result in an increase in the 
serum cholesterol for at least 2 years. This lack of early 
direct response to endogenous oestrogen withdrawal would 
therefore suggest oestrogens to be of no more than secondary 
importance in the known relationship of increasing blood 
cholesterol with age (Keys, 1963; National Centre for Health 
Statistics, 1966). Speculation as to what the primary factor 
or factors that are responsible for differences in cholesterol 
with age and between the sexes may be is beyond the scope of 
the present thesis. 
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The ability of exogenous oestrogen therapy to reduce 
serum cholesterol values appears well documented (Davis et al, 
1961; Oliver and Boyd, 1961; Robinson et al, 1960). In the 
present study, administration of oestradiol valerate 
continuously for 6 months to 50 oophorectomized females 
resulted in a decrease of the total serum cholesterol value 
of possible significance (p <: 0.05). Mixed conjugated 
equine oestrogen administration had no or little effect on 
the cholesterol values. Robi nson et al (1960) reported a 
significant serum choleste~ ol loweri ng effect at 1 month, 
3 months, 6 months and 12 months when administering conjugated 
oestrogens to oophorectomi zed females . There is no obvious 
explanation for the failure of the present study to confirm 
\ 
these findings . The present study may have been inadequste 
in that the period of follow-up may not have been long enough 
to allow a complete exhibition of all trends . A long-term 
study of this nature i s therefore considered to be a 
subject for future investigation . 
Nonetheless, the negative findings of the present 
investigation in relation to the effect of oophorectomy 
on serum cholesterol and the minimal short-term value of 
subsequent exogenous oestrogen therapy to oophorectomized 
females are considered sufficient evidence for questioning 
the empirical use of such hormones for the prevention of 
ischaemic heart d i sease i n postmenopausal women (Davis et al, 
1961; McBride, 1967; Wilson and Wilson, 1963; Wilson et 




5.4 CALCIUM AND PHOSPHORUS METABOLISM 
The effects of the menopause, oophorectomy and oestrogenic 
hormones on plasma calcium and inorganic phosphorus metabolism 
and their relation to osteoporosis are reviewed in Part 1.4.3. 
The plasma calcium, phosphorus and alkaline phosphatase values 
of all patients investigated in the present study are listed 
in Appendix D and the analysis and statistical evaluation of 
these results appears in Part 4.5 
Whereas the present investigation does not confirm 
oophorectomy to result in a signi ficant change in the plasma 
calcium levels, the plasma inorganic phosphorus values 
following oophorectomy presented some difficulty ' in interpretation. 
Phosphorus values after oophorectomy did not differ significantly 
from the mean normal premenopausal values. The group assessed 
two years after hysterectomy with conserved ovaries, however, 
showed a strikingly low value for plasma phosphorus which 
differed significantly from all the other groups investigated. 
These findings suggest the ovary to be effective either in 
producing a reduction in or preventing an elevation of plasma 
inorganic phosphorus and in this respect are in agreement 
with the findings of Szymendera and Madajewicz (1967) and 
Young and Nordin (1967). Young and Nordin (1967) demonstrated 
a significant rise in plasma and urinary calcium and phosphorus 
values after the menopause. In their premenopausal women, 
plasma calcium was 9.32 and phosphorus 3.31 mg/100 ml 
(9.66 and 3 . 61 in the present study). After the artificial 
menopause the corresponding values were 9.81 and 3.62 mg/100 ml 
(9 . 68 and 3.63 in the present study) . They found the rise of 
plasma and urinary calcium to be most apparent during the 
first years after the cessation of the menstrual periods. 
These findings were confirmed by Szymendera and Madajewicz (1967). 
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Young and Nordin (1967)interpreted these changes to mean that 
the menopause i s followed by a rise in bone resorption which 
leads to a rise in plasma and urinary phosphorus. The 
phosphorus values of the present investigation are similar 
and this interpretation is acceptable . The failure of the 
present investigation to confirm the changes in plasma calcium 
with menopause is inexplicable, especially in view of the fact 
that the methods of measurement were similar in both instances 
(Auto-Analyser ) and the effect of oestrogen on plasma calcium was 
so dramatic in the present study . 
The present investigation in fact demonstrated exogenous 
oestrogen therapy to be extremely effective in reducing plasma 
calcium and inorganic phosphorus values in oophorectomized 
females . These findings confirm those of Jasani et al (1965), 
who found that a significant fall of plasma calcium could be 
demonstrated following oestrogen administration provided the 
plasma calcium was measured by Auto-Analyser and not by 
[flame photometry. They suggested, as a result of the i r study, 
,that oestrogen hormones have an action on the blood/bone 
equilibrium antagonistic to the parathyroid hormone . The fall 
in plasma calcium and inorganic phosphorus has been shown to 
be due primarily to reduced bone resorption (Frost, 1961; 
Lafferty et al, 1964). Jasani et al (1965 ) calculated that, 
since the sites of bone loss appear to be highly selective 
(Nordin et al, 1966 ) , a negative calcium balance of only 50 mg 
daily for five years (15 - 20 g calcium would be sufficient 
to destroy a significant amount of trabecular bone . Taken 
into account with the findings and discuss i on above, the 
conclusion of the present investigation i s that exogenous 
oestrogen therapy tends to lower plasma calcium and inorganic 
phosphorus presumably by inhibiting bone resorption. Such 
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therapy is therefore of potential value in the prevention of 
osteoporosis and is indicated, at least, in the premenopausal 
female who undergoes the operation of bilateral oophorectomy. 
These findings in relation to bone metabolism could be used as a 
reason for prescribing oestrogens prophylactically to all women 
for life from the menopause onwards. 
An interesting observation of the present investigation was 
the disparity in effect of the two forms of oestrogen administered. 
Conjugated equine oestrogen was extremely effective in reducing 
the plasma calcium level whereas oestradiol valerate was 
statistically ineffective • . Both oestrogens were effective in 
reducing plasma inorganic phosphorus, the conjugated oestrogens 
being slightly more effective. There are no satisfactory 
comparative trials in the literature. However, Young et al (1968) 
have shown that administration of ethinyl-oestradiol to post-
menopausal women was associated with a small but significant fall 
in plasma calcium and phosphorus. Wallach and Henneman (1959) 
suggested diethylstilboestrol and conjugated equine oestrogens to 
be prophylactic against postmenopausal osteoporosis, their 
observations being clinical and radiological. Hernberg (1960) 
found a negligible reduction in height during ethinyl-oestradiol 
and hexoestrol treatment in comparison to control cases of the 
same age group. Neither Hernberg (1960) nor Wallach and Henneman 
(1959) included calcium kinetic studies in their investigations, 
nor did they differentiate between the specific types of oestrogen 
used. In both in~tances all cases treated were analysed together 
as a single group. The present investigation is therefore con-
sidered of importance in indicating that certain oestrogens are 
more likely to be effective than others in the future management 
of osteoporosis and a strict evaluation of all presently avail-
able oestrogenic substances is considered to be a subject for 
further research. 
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5 . 5 SPECIFIC EFFECTS ASSOCIATED WITH MENOPAUSE AND THE 
ROLE OF REPLACEMENT OESTROGEN THERAPY 
By virtue of a critical review of the medical literature 
and the contribution of the present investigation, it is possible 
to conclude that the menopause, whether artificial or 
spontaneous, is associated with certain other specific clinical 
and metabolic effects. It has been shown, however, that the 
number and variety of such effects is less than currently 
assumed and that in certain situations these changes may be 
only an indirect response to oestrogen withdrawal. 
It is therefore suggested that the following features are 
specifically related to endogenous oestrogen withdrawal, e.g. 
after bilateral oophorectomy 
A. CLINICAL EFFECTS 
B. METABOLIC EFFECTS 
1. Hot flushes and perspiration 
2. Atrophic vaginitis - dyspareuni a, 
pain or blood-stained discharge 
3. Atrophy of breasts 
1. Increase in vaginal parabasal 
cells 
2. Increase in plasma inorganic 
phosphorus 
3. Possible increase in plasma 
calcium 
The increase in plasma calcium and inorganic phosphorus 
appears to be a result of increased bone resorption leading 
ultimately to clinical osteoporosis in a significant number of 
postmenopausal females (Young and Nordin, 1967). 
The normal ovary retained at the time of gynaecological 
surgery in females of reproductive age is demonstrated by this 
study and others (Bancroft-Livingston, 1954; Beavis et al, 1969; 
He l ler et al, 1941; Randall et al, 1957; Whitelaw, 1958) to be 
fully functional for at least two years after operation and 
probably as long as the time of the expected menopause. 
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The advantages have to be balanced against the risks of 
conservation of such ovaries, as discussed in Part 1.5. 
Taking all factors into account, the present study lends 
strength to the arguments in favour of conservation of such 
ovaries and the words of Robert Battey (1828-1895) bear 
repetition 'I believe these organ s should alone be sacrif i ced 
for grave causes, and then only as a dern i er resort, when the 
hitherto recognized resources of our art have been expended 
i n vain . ' 
The specific effects of exogenous oestrogen replacement 
therapy have proved to be : 
A. CLINICAL EFFECTS 
B. METABOLIC EFFECTS 
1. Relief of hot flushes and 
perspiration 
2. Relief of sympt oms of atrophic 
vaginitis (dyspareunia, pain 
and blood-stained discharge ) 
3. Produce feeling of general 
well-being 
4. Produce nausea and vomiting 
1. Reduction of vaginal parabasal 
cells 
2. Reduction of serum cholesterol 
3. Reduction of plasma calcium 
4. Reduction of plasma inorganic 
phosphorus 
The role of exogenous oestrogen replacement therapy would 
thus appear to have been clarified. The indications for such 
therapy may be enumerated as follows 
1. To postmenopausal females complaining of symptoms 
related to hot flushes or atrophic vaginitis 
2. To all females undergoing surgical castration prior to 
the menopause, as a prophylactic against osteoporosis. 
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In this instance a case may also be made for the 
administration of appropriate oestrogens to all females 
from the menopause onwards. 
The symptoms of depression, irritability , angina pectoris, 
insomnia ,and palpitations have been shown to respond adequately 
to placebo therapy and are not therefore indications for 
oestrogen administration to the postmenopausal female. 
Backache has been shown not to respond to oestrogen therapy. 
In the case of libido no effect of therapy has been demonstrated. 
Here the operation of hysterectomy in itself has been shown 
to be the factor of importance in red ucing libido. Thus 
backache and frigidity, too, must fa l l away from the usual 
list of indications for exogenous oestrogen therapy. 
The evidence relating the administration of exogenous 
oestrogens and the prevention of the ageing process has been 
examined and found to be wan.ting Wi lson and Wilson, 1963 ) . 
For example, the present investig·at.ion has shown that these 
hormones are not able to improve the condition of atrophic breasts 
or facial appearance. There i.a therefore no scientific basis 
for such therapy at the present time Dapunt, 1967; Novak, 1 967). 
Finally, the present investigation has been of value in 
demonstrating that the selection of oestrogen is of as much 
importance as the precise indication. It has been shown that 
different oestrogens have different effects. Thus, one 
particular oestrogen may be more effective than another for a 
specific indication and the l ogical conclusion is that where 
several specific effects are required a mixtur e of different 
oestrogens may be necessary . For example, oestradiol valerate 
was of value in reducing serum cholesterol and conjugated equine 
oestrogens were not; on the other hand, conjugated oestrogen 
therapy demonstrated a strong plasma calcium reducing property 
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after oestradiol valerate had proved to be ineffective. 
The hope for the future is that oestrogenic substances will 
be developed with properties specific to one or other metabolic 
process. Thus the physician using such hormones may acquire an 
armamentarium of oestrogenic substances, each affecting a 
different target organ . 
The prime objective of the present thesis has been to 
place the 'menopause' on a scientific basis; the scope for 
further investigation and advance has been shown to be 
considerable. 
PART 6 
SUMMARY AND GENERAL CONCLUSIONS 
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6 • SUMMARY AND GENERAL CONCLUSIONS 
The clinical and metabolic effects of the postmenopause 
have received inadequate scientific consideration. In 
particular, removal of normal ovaries at the time of hysterectomy 
on women of reproductive age has been undertaken too lightly 
because of insufficient knowledge or awareness of the possible 
disadvantageous clinical and metabolic effects of such surgery. 
It was thus considered that a study directed at clarifying 
the true clinical and metabolic effects of the menopause 
as produced by surgical castration, and the role of replacement 
oestrogen therapy, was necessary. 
Accordingly, the aims of this thesis, as outlined in 
Part 2, were 
1. to determine the real clinical effects of bilateral 
oophorectomy on the human female, 
2. to determine, should any clinical effects be shown, 
whether such effects could be reversed b¥ exogenous 
oestrogen replacement therapy, 
3. to study the changes in vaginal smear following bilateral 
oophorectomy and subsequent oestrogen therapy, 
4. to study the effects of oophorectomy and subsequent 
oestrogen therapy on plasma cholesterol values in an 
identical group of patients, 
5. to determine whether plasma calcium and inorganic 
phosphorus values were altered by oophorectomy and if so 
whether subsequent exogenous oestrogen therapy to the same 
group of patients could reverse this effect, 
6. to consider the clinical and metabolic effects of bilateral 
oophorectomy with special reference to the place of this 
operation in gynaecology at the time of routine abdominal 
- 94 -
hysterectomy for benign conditions; also to evaluate the 
role of replacement oestrogen therapy to all females 
after the menopause, 
7. to determine whether - different oestrogens have similar or 
different effects by conducting a controlled comparative 
evaluation of two different forms of commercially 
available oestrogen and a placebo. 
To provide a background to these studies, relevant aspects 
of the literature, dealing with the historical background 
(Part 1 . 2), clinical effects of the climacteric (Part 1.3), 
metabolic effects of the climacteric (Part 1 .4), the indications 
and incidence of oophorect omy (Part 1.5) and the present 
position of oestrogen replacement therapy (Part 1.6) were 
critically reviewed . 
Female patients, selected according to specific criteria 
(Part 3.1) ,were investigated through a Menopause Clinic 
established for clinical research purposes at the Groote Schuur 
Hospital, Cape Town. The patients investigated were divided 
into 7 sub-groups according to whether they were pre- or post-
menopausal and whether uterus and ovaries were intact or 
hysterectomy had been performed at specific time intervals, 
with and without removal of ovaries (Part 3.1) 
Following initial evaluation of clinical features 
(Part 3.2.2), plasma total cholesterol,calciurn, inorganic 
phosphorus and alkaline phosphatase (Part 3.2.3) and accurately 
measured vaginal smear maturation index (Part 3.2.4), the 
oophorectomized patients, fifty in number, received oestradiol 
valerate 4 mg daily continuously for 6 months (Part 3.2.5). 
Repeat evaluations at 3 months and 6 months preceded single 
blind substitution of oestradiol valerate by placebo. After 
3 months' therapy, placebo was changed to 5 mg conjugated 
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equine oestrogen daily for 3 months. Evaluations were 
repeated at each substitution and following the conjugated 
equine oestrogen therapy . All data was recorded on special 
trial forms (Appendi x A) and the data ultimately transferred 
to computer cards for the analysis and statisti cal evaluation 
(Part 3.2 . 6). 
The following results were obtained: 
1. The symptom of hot flushes and associated perspiration 
J 
is shown to be oestrogen dependent - oophorectomy results 
v· 
in a striki ng increase in t he i ncidence of hot flushes 
and oestrogen therapy, irrespective of t ype, significantly 
relieves the symptom (p <:0.001 . Moreover, in this respect 
it is shown that the conserved ovaries are still functional 
two years after hysterectomy {p <0.01) Part 4.1.1.) 
2. Clinical atrophic vag i nitis i s shown to occur commonly in 
i./ the oophorectomized female and to respond dramatically to 
oestrogen therapy p <0.001 ) (Part 4 . 1 . 2. ) 
3. Headache is proven to be unrelated to removal of ovaries,but 
possibly relieved by conjugated oestrogen therapy (p <:o.05). 
-~ Oestradiol valerate was not effective in relieving this 
symptom (Part 4 .1.3. 
4. The response of palpitations to placebo therapy (p <:0.05) 
and the s i milar incidence of this symptom in all groups 
.,,/'. prior to therapy indicate that palpitations are unrelated to 
oophorectomy and explain the lack of response to oestrogen 
therapy (Part 4.1 . 4. ) 
5. Angina pector i s is shown to be a symptom related to 
./ oophorectomy (p < O. 01 ) but unrelieved by oestrogen therapy. 
Nevertheless, there is some relief of angina pectoris by 






The symptom of insomnia appears to be unrelated to 
oophorectomy, nor can it be relieved by oestrogen therapy. 
As expected in this situation, it demonstrates a striking 
response to placebo therapy (p <0.001) (Part 4.1.6.) 
Irritability is not a response of oophorectomy and is 
relieved essentially by placebo therapy (p < O. 05) • 
Conjugated oestrogens, however, produce more relief of 
this symptom (p < o. 05) but this may be part of the general 
mood elevating effect of oestrogens (Part 4.1.7). 
8. Observations seem to indicate that the operation of 
oophorectomy results in depression (p <:0.05), which is 
~ probably psychologically orientated in view of the highly 
significant response to placebo therapy (p < 0.001). 
There is no response directly attributable to oestrogen 
therapy (Part 4.1.8). 
9 . Low backache is not proven to be a factor related to 
oophorectomy and is not relieved by oestrogen therapy. 
J It is considered significant that low backache, being more 
real a symptom than, for example, insomnia or depression, 
showed no placebo response to therapy (Part 4.1.9). 
10. The operation of hysterectomy, irrespective of whether 
/ 
the ovaries are removed or no(, is shown to be associated 
/ with a highly significant reduction of libido (p < 0.001) • 
Oestrogen therapy has no beneficial effect on decreased or 
absent libido (Part 4.1.10). 
11. 
J 
Oestrogen and placebo therapy are both demonstrated to have 
a highly stimulating 'mental tonic' effect on the patient 
and this is borne out by both the observer's assessment 
and the patient's impression (p <:0.001). However, single 
blind cross-over from oestrogen to placebo resulted in a 
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significant deterioration in the patient's overall feeling 
of well-being (p <o.Ol ) . In this respect both forms of 
oestrogen used in this trial were effective (p < 0.01). It 
is therefore considered that the 'tonic effect' of oestrogen 
has been proven to exist (Part 4.1 . 12 ). 
12. Administration of oestrogens to oophorectomiz.ed females is 
shown to produce no significant change in the body weight 
(Part 4. 2 .1 ) • 
13. Oestrogen therapy does not appear to cause a change in the 
diastol i c blood pressure (Part 4.2.2 ). 
14 . Oophorect omy results in a significant degree of breast 
atrophy (p < 0.001). However, an unexplained finding is 
I 
a high i ncidence of atrophic breasts in the group of patients 
investigated 2 years after hysterectomy with conservation 
of ovar i es as compared to a normal premenopausal group 
(p < 0.001) . Moreover, exogenous oestrogen therapy is shown 
to be of no value in restoring atrophic breasts to a normal 
premenopausal state (Part 4.2.3) . 
15. The vaginal smear results were unexpected. The superficial 
16. 
/ 
cell count proved to be an unreliable guide to the oestrogenic 
state of the groups investigated. However, oophorectomy is 
shown to produce a statistically highly significant increase 
in the parabasal cell count (p <: 0.0005 ) and this response 
is reversed by the administration of exogenous oestrogens, 
irrespective of the type used (p < 0.0005) (Part 4. 3). 
The present investigation does not confirm oophorectomy to 
result i n a significant increase in the serum cholesterol. 
Oestrogen therapy in the form of oestradiol valerate was 
shown to be of value in reduc i ng the total serum cholesterol 
value (p < 0.05) (Part 4. 4) . ·-..... 
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the plasma calcium value, conjugated equine 
but not oestradiol valerate was shown to be 
extremely effective in reducing the plasma calcium 
(p < 0.0025) (Part 4. 5). 
18. Plasma inorganic phosphorus values after oophorectomy did 
not significantly differ from the mean normal premenopausal 
values. The 2 year post-hysterectomy-retained-ovaries 
group showed a strikingly low value which differed 
significantly from all the other groups investigated. 
Although these findings suggest that the ovary is effective 
in producing either a reduction in or preventing an elevation 
of plasma inorganic phosphorus, it is impossible to place 
any strict interpretation on these results. Nevertheless, 
exogenous oestrogen replacement therapy is shown to be 
effective in reducing plasma inorganic phosphorus and this 
property is common to both forms of oestrogen used (Part 4.5). 
19. The only significant complication of oestrogen therapy 
demonstrated was a high incidence of nausea and vomiting. 
This effect was c9mmon to both forms of oestrogen administered 
and is considered to be related to the high dosage of 
hormone used for the purposes of this trial. 
In essence, therefore, the findings in the present thesis 
have led to the following conclusions 
1. The only symptoms directly associated with the menopause 
and occurring specifically after oophorectomy are those 
related to hot flushes and atrophic vaginitis. In turn 
these symptoms are the only ones to be specifically relieved 
by exogenous oestrogen therapy. 
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2. Ovaries conserved at the time of hysterectomy i n women of 
reproductive age have been shown to be effective in 
preventing postoperative menopausal symptoms for at least 
2 years. 
3. The symptoms of depression, irritab ility, angina pectoris, 
insomnia and palpitations respond significantly to placebo 




The operation of hysterectomy, with or without conservation 
of ovaries, dele~eriously affec ts libido . , . 
The 'tonic effect' or ability of oestrogens to generate 
a feeling of well-being has been shown to exi st . 
6. Exogenous oestrogen has been shown to be of no value in 
the preventi on or reversal of atrophy of the breasts of 
postmenopausal women. 
7. Different oestrogens have d ifferent clinical and metabolic 
effects. 
8. The percentage of vaginal parabasal cells is the most reliable 
cytologic index of the oestrogenic status of the post-
menopausal female . Oophorectomy results in a significant 
increase in the number of these cells and exogenous oestrogen 
therapy reverses this effect. The vagina~ superficial cell 
shows no relationship to menopause and oophorectomy,and there 
is a poor response by these cells following exogenous 
oestrogen therapy to oophorectomized women. 
9. Bilateral oophorectomy in the premenopausal female does 
not result in an increase in the serum cholesterol for at 
least 2 years. Oestrogen therapy, however, reduces the serum 
choles tero values of oophorectomized females and may be of 
possible clinical benefit . 
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10. Exogenous oestrogen therapy tends to lower plasma calcium 
and inorganic phosphorus, presumably by inhibiting bone 
resorption. Such therapy is therefore of potential value 
in the prevention of osteoporosis and is indicated, at least, 
in the premenopausal female who undergoes the operation of 
bilateral oophorectomy. By similar argument it would appear 
in this instance that there is some case for administration 
of appropriate oestrogens to all women from the menopause 
onwards. The present investigation, furthermore, is 
considered of importance in indicating that certain oestrogens 
are more likely to be effective than others in this respect. 
11. Finally, it is concluded that ovaries of normal appearance 
should not be removed from women of reproductive age at 
the time of hysterectomy for benign indications. 
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A P P E N D I C E S 
APPENDIX A 
TRIAL FORM AND EXPLANATORY CODE 
The trial {survey) form was designed for numerical 
cataloguing and assessment of each patient investigated 











This provides for a general description of 
the patient and for general administrative 
and organizational details 
3. SI GNS 4 , INVESTIGATIONS. These sections 
are self-explanatory. The numerical translation 
of each of the parameters measured or assessed 
is explained by the code sheet 
This section allowed for the details of 
treatment prescribed at each visit to be 
recorded 
RELATED DISORDERS. The measurement of factors 
74 (Overall Impression ) , 79 (Patient's 
assessment) and 80 (Husband's assessment) is 
discussed under Section 3.2.2. The related 
disorders listed (items 75, 76, 77 and 78) 
which allow for a trial of long-term oestrogen 
replacement therapy and are enumerated in the 
explanatory code, do not apply strictly to the 
present thesis. 
OESTROGEN REPLACEMENT SURVEY 
Dr. Wulf Utian 
NOT FOR CODING Name .............................................................................................. ............ Hospital No .................................................................. . 
History: Gynae............................................. ....................................... General ................................................................ .. 
Photo Taken: Face and Profile ......................................................................................................... ...................................... . 









































Indication for Hysterectomy 
Previous Treatment 
Date of Visit: Day 
Month 
Year 
Months since Oophorectomy or Menopause 



















Blood Pressure (Diastolic) 
Facial Hair 
Acne 
Hair Texture (Scalp) 
Skin Thickness: Subscapular 
Arm 
Height (inches) 
50 Breast Development 
51 Vaginal Discharge 
























aAagmav:.ial .Uigpi;y Phosphorus (Mg/100 ml) 
X-ray Lumbar Spine 
Alkaline Phosphatase 
Serum Calcium (Mg./lOOml.) 






RELATED 75 Myocardial Infarction 
DISORDERS ··· .. ············ ............................... ..... .............. ... ............................ ....................................................................................................................................................... ....... .. .. .... .. 









































OESTROGEN REPLACEMENT CODE 
0 = NORMAL PREMENOPAUSAL 
l = PREMENOPAUSAL >,45 YEARS 
2 = NORMAL POSTMENOPAUSAL 
3 = POSTMENOPAUSAL + SYMPTOMS 
+ SYMPTOMS 
(UNOPERATED) 
4 = PREMENOPAUSAL TREATED IMMEDIATE POST B.S.O. 
5 = PREMENOPAUSAL TREATED 6 MONTHS II II II 
6 PREMENOPAUSAL TREATED 2 YEARS II II II -
7 = POSTMENOPAUSAL TREATED IMMEDIATE POST B.S.O. 
8 = 6 MONTHS POST HYSTERECTOMY - RETAINED OVARIES 
9 = 2 YEARS POST HYSTERECTOMY - RETAINED OVARIES 
UNKNOWN 18-19 MONTHS ON TREATMENT 
WHITE 
COLOURED 0 = PRE. OP CONTROL 
BANTU 1 = CONTROL 
OTHER 2 = 1 MONTH THERAPY 
3 = 3 MONTH THERAPY 
4 = 6 MONTH THERAPY 
5 = 2 MONTH PLACEBO 
6 = 3 MONTH PREMARIN 




WIDOWED 20 HOT FLUSHES 
0 = UNKNOWN 
1 - ABSENT 
FOR HYSTERECTOMY 2 = 0-3 
3 = 4-6 UNKNOWN 4 = 7-9 DYSFUNCTIONAL 
5 = 10-12 BLEEDING 
6 13-15 = CHRONIC INFECTION 7 = 16-18 BENIGN TUMQURS 8 = 19-21 MALIGNANCY - CORPUS 9 = 22 OR MORE MALIGNANCY - CERVIX 
ENDOMETRIOSIS 
OTHER 
PRQL]\.PSE 21-35 ALL OTHER SYMPTOMS NO'r DONE 
0 = UNKNOWN 
1 = ABSENT 
PREVIOUS TREATMENT 2 = SLIGHT 3 = MODERATE 
0 = UNKNOWN 4 = SEVERE 
1 = ANALGESIC 5 = NORMAL 
2 = TRANQUILIZER 
3 = OESTROGEN 
4 = PROGESTOGEN 
5 = OEST. + TRANQ. 27 MOOD CHANGES 
6 = SURGICAL 
7 0 = UNKNOWN = NIL 
8 1 = NO CHANGE = ANDROGEN - OESTROGEN 
9 2 = IMPROVED = 3 = DETERIORATED 
30 DEGENERATIVE ARTHROPATHY 
0 = UNKNOWN 
1 = OSTEO . OF FINGERS 
2 = BACKACHE 
3 = NORMAL (ABSENT) 
4 =GEN.JOINT PAINS 
36 MISCELLANEOUS 
0 = UNKNOWN OR NIL 
1 = ALLERGIC REACTION 
2 = GASTRIC PAIN 
3 = LOW BACK PAIN 
4 = SUPERFICIAL PHLEBITIS 
40 BLOOD PR . 
0 = UNKNOWN 
l = 90 OR LESS 
2 = 90 - 120 
3 = 120 - 150 
4 = 150 - 180 
5 = 180 OR HIGHER 
41 . FACIAL HAIR & 42 ACNE 
AS FOR 21 - 35 
43 HAIR TEXTURE 
0 = UNKNOWN 
1 = NO CHANGE 
2 = SLIGHT 1'.,0SS 
3 = SEVERE LOSS 
4 = SLIGHT GAIN 
5 = EXCESS GAIN 
50 BREAST DEV. 
0 = UNKNOWN 
l = NORMAL PREMENOP . 
2 = ATROPHIC 
3 = SECRETING 
4 = CANCER 
5 = MASTOPATHY 
6 = MASTODYNIA 
51 VAG . DISCHARGE 
0 = UNKNOWN 
l = ABSENT 
2 = BLOOD-STAINED 
3 = PHYSIOLOGIC 
4 = TRICHOMONAS 
5 - MONILIA 
6 = NON-SPECIFIC 
7 = ATROPHIC VAGINITIS 
8 = 
58 E.C.G c 
0 = UNKNOWN 
1 = NORMAL 
2 = CORONARY ISCHAEMIA 
3 = OLD INFARCT 
4 = RECENT INFARCT 
5 = HYPERTENSIVE 
6 = CARDIAC ARRHYTHMIAS 
61 X-RAY LUMBAR SPINE 
0 = UNKNOWN 
1 = NORMAL 
2 = OSTEOPOROSIS 
3 = VERTEBRAL COMPRESSION 
(COLLAPSE) 
4 = OSTEO-ARTHRITIS 
5 = MARKED DISC NARROWING 
6 = SLIGHT DEG. CHANGES 
7 = FURTHER DETERIORATION 
OF PATHOLOGY 
70 OESTRADIOL VALERATE 
DOSE PER DAY 
0 = UNKNOWN 
1 = NIL 
2 = 2 mg ~ 
3 = 4 mg . 
4 = 6 mg . 
5 = 8 mg. 
6 = 10 mg. or more 
7 = 2 mg. every 2nd day 
71 OESTRADIOL VALERATE MODE 
0 = UNKNOWN 
1 = CONTINUOUS 
2 = CYCLICAL 
3 = NIL 
72 PLACEBO 











1 = CONTINUOUS 







= 2.5 mg conj. 
= 1.25 mg conj . 
= 5.0 mg conj. 





75-78 RELATED DISORDERS 
0 = UNKNOWN 
l = ABSENT 
2 = BEFORE TREATMENT 
3 = DURING TREATMENT 
4 = AFTER TREATMENT 
74 RESULT 79 PATIENT & 
80 HUSBAND 
0 = UNKNOWN 
1 = MARKED IMPROVEMENT 
2 = SLI GHT I MPROVEMENT 
3 = UNCHANGED 
4 = SLI GHT DETERIORATION 
5 = MARKED DETERIORATION 
75 - 5 = PREVIOUS DEEP VEIN 
THROMBOSIS 
APPENDIX B 
VAGINAL EPITHELI AL CELL COUNTS OF ALL PATIENTS AT EACH 




INTERMEDIATE SUPERFI CI AL CELL TYPES) 
CELL COUNTS OF ALL OOPHORECTOMI ZED 
PATIENTS AT EACH VIS I T 
CELL COUNTS OF NORMAL PREMENOPAUSAL 
GROUP AND GROUPS WITH CONSERVED 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE B.2 CELL COUNTS REPRESENTED AS MATURATION INDICES 
OF NORMAL PREMENOPAUSAL GROUP AND GROUPS WITH 
CONSERVED OVARIES AFTER HY'STERECTOMY 
\ 
GROUP DESCRIPTION PATIENT PARABASAL INTERMEDIATE SUPERFICIAL CLINIC 
NUMBER 
Normal 31 0 99 1 
premenopausal 32 0 97 3 
(9 patients) 5!:> 1 99 0 
60 0 75 25 
71 0 70 30 
105 0 ( 92 8 
1 06 10 85 5 
107 0 99 1 
108 'O 85 15 
6 months post- 3 0 90 10 
hysterectomy 15 0 99 1 
with conserved 7 0 95 5 
ovaries 85 0 98 2 
(8 patients ) 90 - 0 99 1 
96 0 85 15 
01 20 80 0 
03 0 97 3 
' 
2 years post- l 0 92 8 
hysterectomy 63 0 98 2 
with conserved 64 15 80 5 
ovaries 65 0 99 1 
(18 patients) 66 0 99 l 
67 0 99 1 
75 0 50 50 
76 0 96 4 
78 1 99 0 
80 1 82 17 
83 0 97 3 
84 0 95 5 
89 1 99 0 
94 4 93 3 
97 2 96 2 
98 0 97 3 
101 20 80 '. ,._ 0 
" 104 0 93 \ 7 
,~~ ... 
APPENDIX C 




BLOOD CHOLESTEROL VALUES IN 
MG PER 100 ML OF ALL 
OOPHORECTOMIZED PATIENTS AT 
EACH VISIT 
BLOOD CHOLESTEROL VALUES OF 
NORMAL PREMENOPAUSAL GROUP AND 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE C.2 BLOOD CHOLESTEROL VALUES (MG PER 100 ML) 
OF NORMAL PREMENOPAUSAL GROUP AND GROUPS 
WITH CONSERVED OVARIES AFTER HYSTERECTOMY 
PATIENT 
GROUP DESCRIPTION CLINIC CHOLESTEROL 
NUMBER 









6 months post- 3 243 
hysterectomy with 15 191 






2 years post- 1 251 
hysterectomy with 63 263 

















PLASMA CALCIUM, PHOSPHORUS AND ALKALINE 





PLASMA CALCIUM VALUES, IN MG PER 100 ML 
OF ALL OOPHORECTOMIZED PATIENTS AT 
EACH VISIT 
PLASMA INORGANIC PHOSPHORUS VALUES, IN 
MG PER 100 ML, OF ALL OOPHORECTOMIZED 
PATIENTS AT EACH VISIT 
PLASMA ALKALINE PHOSPHATASE VALUES, IN 
BODANSKY-REINHART UNITS, OF ALL 
OOPHORECTOMIZED PATIENTS AT EACH VISIT 
PLASMA CALCJUM, INORGANIC PHOSPHORUS AND ,, 
ALKALINE PHOSPHATASE VALUES OF THE NORMAL 
PREMENOPAUSAL GROUP AND THE GROUPS WITH 
CONSERVED OVARIES AFTER HYSTERECTOMY 
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